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1 Introduction 
1.1 Hypersensitivity 1 
Hypersensitivity reactions are disorders caused by aberrant immune responses leading to 
tissue injury and disease. The term sensitivity was first used to define immunity based on 
the fact that an individual becomes sensitised at first contact with an antigen and exhibits a 
reaction at subsequent exposures resulting from the specific interactions between the 
antigen and antibodies or sensitised lymphocytes. As hypersensitivity diseases represent a 
clinically heterogeneous group of disorders there are different approaches for their 
classification. The more typical classification is based on the type of immune response and 
defence strategies that the body uses. Other classifications divide hypersensitivity diseases 
according to the location and type of the antigen, the immunopathological origin of the 
reaction or the timeframe until symptoms appear after antigen exposure.1 
1.1.1 The Gell-Coombs classification of hypersensitivity reactions 2 
In 1963 Gell and Coombs classified hypersensitivity reactions according to the type of 
immune response and the effector mechanisms responsible for tissue and cell injury.3 This 
classification is still widely used, although it encounters more and more criticism. The 
classification has remained unchanged since its development more than 40 years ago even 
though the understanding of the immune system has dramatically increased.4 Many of the 
immunological reactions to drugs do not fit into this classification 4, nor does it take into 
account that more than one type of immune response may take place during a 
hypersensitivity reaction.2, 5  
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Table 1.1 The four types of hypersensitivity reactions according to Gell and Coombs. 2 
 
 
 
Table 1.1 shows the characteristics of the four hypersensitivity reactions following 
sensitisation according to Gell and Coombs. Types I to III are mediated by antibodies 
while type IV reactions are T-cell mediated.  
In immediate hypersensitivity reactions (type I), sensitisation involves the production of 
antigen specific IgE antibodies which bind to high-affinity receptors on tissue mast cells 
and basophils. Re-exposure to the antigen results in cross-linking of the membrane-bound 
antibodies and degranulation of the cells, releasing vasoactive amines such as histamine, 
lipid mediators and cytokines. This reaction begins rapidly and has major pathologic 
consequences such as vasodilation, bronchoconstriction and induction of inflammation.  
Type II antibody-mediated hypersensitivity involves IgG and IgM antibodies against cell 
surface or extracellular matrix antigens. The antibodies opsonise cells and activate the 
complement system generating products that also opsonise cells. This leads to 
phagocytosis of the tagged cells. Deposited antibodies may recruit and activate neutrophils 
and macrophages by binding to the Fc receptor or complement activation with consequent 
inflammation and tissue injury. 
Type III hypersensitivity is induced by circulating immune complexes of IgG or IgM and 
antigens. The deposited immune complexes activate the complement system and thereby 
attract polymorphonuclear leukocytes. The release of neutrophil granule enzymes and 
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reactive oxygen intermediates leads to acute inflammation and tissue injury. The local 
inflammatory response to the deposition of immune complexes is also known as the Arthus 
reaction and is dependent on the antigen/antibody ratio. At low antigen doses and antibody 
excess the complexes are rapidly precipitated, efficiently cleared and therefore do not 
damage. When the antigen is present in a slightly excess in contrast, immune complexes 
are deposited in various vessels which is the cause of many systemic immunological 
diseases. 
Type IV hypersensitivity reactions or cell-mediated reactions are caused by T lymphocytes 
either by directly killing target cells or by triggering delayed-type hypersensitivity (DTH). 
In DTH, sensitised T lymphocytes get activated by tissue antigens and respond by 
secreting cytokines that stimulate inflammation and activate phagocytes. Direct killing of 
tissue cells by sensitised cytolytic T lymphocytes is observed in some diseases. 
1.1.2 IgE-mediated type I hypersensitivity 
Clemens von Pirquet, an Austrian paediatrician and scientist, was the first to use the term 
“allergy” in 1906 for his concept that in immunised organisms immune responses to an 
agent which are host-protective can also be responsible for diseases.6 In correlation with 
the emergence of the term “hypersensitivity” which refers to undesirable immune reactions 
and the Gell-Coombs classification, allergy denotes nowadays the IgE-mediated type I 
hypersensitivity reactions. The allergic reaction is provoked in sensitised individuals by re-
exposure to a specific antigen, in this case also called allergen. These allergens are usually 
common environmental proteins or chemicals to which an individual can be exposed 
through inhalation, ingestion, skin contact or injection. The typical type I hypersensitivity 
reaction experiences a defined sequence of events.1 
1.1.2.1 Pathogenesis of allergic reactions 
Immediate hypersensitivity diseases require introduction of an allergen into the organism, 
antigen capture and processing by an antigen presenting cell (APC) and transport to 
draining lymph nodes. There the processed allergen peptides called epitopes which are 
bound to the major histocompability complex II on the APCs’ surface are presented to 
naïve T lymphocytes. Naïve CD4+ T cells with the specific receptor for the presented 
epitope become activated and differentiate either into the TH1 or TH2 subset of effector 
T helper cells. In the case of allergen sensitisation, the TH1/ TH2 balance tends towards the 
TH2 subtype due to the effect of co-stimulatory molecules and cytokines. The cytokines 
released by these TH2 primed cells interleukin (IL) IL-4 and IL-13 stimulate heavy chain 
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isotype switching to the IgE class in B cells. The prerequisite interaction between TH2 and 
B cells for this to occur also requires antigen-induced activation of the B cell which 
involves antigen binding, processing and presentation by the B cell to differentiated 
T helper cells via the MHC II. The circumstance that the TH2 and the B cell get activated 
by the same antigen ensures a specific immune response to the eliciting allergen. The TH2 
activated cell recognises the antigen presented by the B cell and the cells are stimulated to 
express CD40 ligand which binds CD 40 on the B cell. The released cytokines IL-4 and 
IL-13 act on B cells to proliferate and differentiate into IgE secreting cells. The circulating 
IgE sensitises mast cells, basophils and eosinophils by binding to their high affinity FcεRI 
receptor. This first phase of immediate hypersensitivity reaction is called the sensitisation 
phase.1, 7 
The effector phase of an allergic reaction is initiated upon second exposure to the allergen. 
At the site of entry the antigen binds to the cell surface bound IgE. Cross-linking of two 
membrane bound IgE antibodies occurs when the two bind to different epitopes on one 
antigen molecule or to the same epitope on an allergen dimer. The binding of a multivalent 
antigen resulting in cross-linking of FcεRI initiates a signal cascade in tissue mast cells 
which leads to degranulation of the cell and the release of pro-inflammatory mediators. 
Among the molecules released by mast cells and basophils on activation are histamine, a 
vasoactive amine, lipid mediators like the platelet activating factor, enzymes (e.g., 
tryptase) and the cytokines IL-4, IL-13, IL-3, IL-5, TNF-α and granulocyte macrophage 
colony-stimulating factor (GM-CSF). The cytokines IL-4 and IL-13 perpetuate the TH2 
response whereas IL-3, IL-5 and GM-CSF promote eosinophil production and activation. 
The immediate response to antigen challenge is an inflammatory reaction due to IgE-
mediated mast cell activation and the activity of histamine and lipid mediators causing 
vascular leak, bronchoconstriction and intestinal hypermotility. This occurs only minutes 
after repeated allergen exposure. The late-phase reaction is thought to be initiated by 
eosinophil and neutrophil recruitment and accumulation of inflammatory leukocytes. 
Symptoms of the late-phase reaction appear after 2-4 hours of allergen exposure and can 
last for approximately one day and are manifested by smooth muscle contraction, sustained 
oedema, nasal discharge, airway narrowing, sneezing, coughing, and wheezing. Repeated 
or prolonged exposure to an allergen can cause long-term illness by converting the late-
phase reaction into a chronic inflammatory response. The persistently active and mediator 
releasing eosinophils in chronic allergic diseases lead to serious tissue damage and also 
tissue remodelling.3 
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Of all the allergic reactions the most dramatic and systemic form is probably anaphylaxis 
where the systemic presence of an antigen leads to bronchoconstriction and vasodilation 
throughout the body resulting in oedema in many tissues and a fall in blood pressure which 
can be fatal.1 
1.1.2.2 Aetiology of allergic reactions 
An immediate hypersensitivity reaction is the immune system’s harmful response in 
allergic individuals to environmental antigens which normally are benign for healthy 
people. It is clear that allergy is caused by a TH2 biased immune response to an antigen but 
the mechanisms underlying the preferential differentiation into TH2 subset instead of TH1 
is not completely understood yet. The presence of IL-4 is crucial during antigen 
presentation for naive CD4+ T cells to develop into TH2 cells but its source remains 
obscure.8 
One explanation may be the genetic predisposition in atopic individuals. Although the 
terms allergy and atopy are commonly used as synonyms, “atopy” originally defined a 
genetically predisposed disease characterised by the ability of B lymphocytes to synthesise 
IgE antibodies against ubiquitous antigens able to activate the immune system after 
exposure.2 It has been shown that CD4+ T helper cells in atopic individuals produce 
aberrantly high amounts of IL-4 and IL-5 and also that an overall higher IgE level is linked 
to markers in the IL-4 gene of chromosomes 5q and 11q. The IL-4 gene has been subject of 
several analyses and revealed the role of atopy-associated polymorphisms.9, 10 
The subset of T regulatory (TReg) cells have been identified as key players in the regulation 
of immunological processes and opened the discussion for novel concepts in the 
pathogenesis of allergy. In successful allergen-specific immunotherapy it has been 
observed that IL-10 and TGF-β secreting TReg cells were able to inhibit the development of 
allergic TH2 responses. Also, the T-cell repertoire to allergens in healthy individuals 
recognises the same epitopes as in allergic patients.11 Based on this observation it was 
thought that tolerance in a healthy immune response may be due to active regulation. The 
functions of IL-10 and TGF-β on immune effector cells are depicted in Figure 1.1.  
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Figure 1.1 The role of IL-10 and TGF-β secreting TReg cells (red line, suppression; black 
line, stimulation).12 
 
Analysis of the TH subsets involved in the reaction against common environmental 
allergens in healthy and allergic individuals revealed that the IL-10 secreting TReg susbset 
was the most abundant in healthy immune response. Normal and allergic individuals 
possess all 3 allergen-specific T cell subsets (TH1, TH2 and TReg) but in different 
proportions so that the concept of deficiency in antigen-specific control of effector T cells 
by T regulatory cells in allergic patients was established.12 
Another but much disputed explanatory approach for the development of allergic diseases 
is the so called “hygiene hypothesis”.13 Although an inverse relationship between 
infections and allergic diseases has been observed in most developed countries, the 
mechanisms behind the suggestion that exposure to microbial agents in childhood may 
inhibit the development of allergic diseases remain unclear. Also inconsistent findings 
often challenged the hypothesis. However, the hygiene hypothesis may be a credible 
explanation but is surely not the only one for the increase in allergic diseases over the past 
decades.14 
1.1.3 Food allergy 
In 1995 the European Academy of Allergy and Clinical Immunology has proposed a 
classification of adverse food reactions depending on the pathogenic mechanisms shown in 
Figure 1.2. Depending on whether or not the reaction is immune-mediated, it should be 
termed food allergy or food intolerance.15 
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Figure 1.2 Classification of adverse reactions to food.16 
 
There exist two main types of adverse reactions to food: toxic and non-toxic reactions.16 
Food intolerance (nonallergic food hypersensitivities) includes all non-toxic adverse 
reactions to food when the immune system is not involved. This can be due to enzymatic 
food intolerance (e.g. lactase deficiency), pharmacological reactions (e.g. to biogenic 
amines) and unclear causes, such as certain irritants and psychosomatic responses. As can 
be seen in the diagram there are two different types of immune-mediated reactions to food, 
namely reactions of type I hypersensitivity and type III or IV hypersensitivity. As 
symptoms of IgE-mediated food allergy like oral allergy syndrome (OAS), gastrointestinal 
symptoms, urticaria or allergic rhinitis and non-IgE-mediated food allergies and food 
intolerances may resemble each other, there is no simple diagnostic test for food 
allergies.17 The actual prevalence of food allergy is therefore very hard to determine. 
Perceived food allergies largely overestimate true food allergy because the general 
population cannot be expected to differentiate IgE-mediated food allergy, non-IgE-
mediated food allergy, allergic food hypersensitivity and non-allergic food 
hypersensitivity. Hundreds of studies concerning the epidemiology of food allergy have 
been considered in the statement that more than 1-2% but less than 10% of the worldwide 
population are affected and it is unclear if the prevalence of food allergies is increasing.18 
Despite remaining uncertainty about the prevalence of food allergies, it is generally 
acknowledged that this disease impacts the health of the general population and that further 
studies are warranted.19 
1.1.4 Fish allergy 
Despite the varied human diet and the fact that virtually any food could trigger allergic 
reactions only a limited number is responsible for the vast majority of food-induced 
allergic reactions. Major allergen sources responsible for most of the significant reactions 
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are milk, egg, peanut, tree nuts, fish, shellfish, wheat and soy.20 Fish allergy belongs to 
class 1 food allergies where the sensitisation to the food allergen itself occurs in the 
gastrointestinal tract.21 Fish especially plays an important role in human nutrition since it is 
a valuable source of proteins and contains large amounts of omega-3 polyunsaturated fatty 
acids and fat-soluble vitamins.22 Due to physicians’ recommendation to increase fish 
consumption and enhanced fish production the recent prevalence of fish allergies of 2% is 
estimated to rise in the future.19, 23, 24 
Fish allergy is associated with IgE-mediated hypersensitivity reactions to parvalbumins, 
which are small calcium-binding muscle proteins, and represent the major and sole 
allergens for 95% of fish-allergic patients.25, 26 The major fish allergen parvalbumin 
represents an extremely abundant allergen in many fish species 26 and the calcium-bound 
form has been shown to be remarkably stable.27, 28 Boiling and cooking of fish can also 
lead to the formation of molecular aggregates and enhancement of IgE reactivity as shown 
for tuna, salmon, cod, flounder and whiff.28, 29 
From an evolutionary point of view the family of parvalbumins can be divided into two 
distinct lineages known as the α- and β-parvalbumins.30 Representatives of α-parvalbumins 
can be found in muscle of fish, amphibians, birds and mammals but are generally not 
allergenic. Although the folds of α- and β-parvalbumins are very similar, the often 
allergenic β-parvalbumins only share 56% sequence identity with the human α-
parvalbumin. The β-parvalbumins are found in many fish species as depicted in Figure 
1.3.31 It has been shown that the dark muscle of fish is significantly less allergenic than the 
white muscle, due to unequal distribution of the allergen molecule β-parvalbumin.32 
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Figure 1.3 Dendrogram of parvalbumin sequences (scale bar shows the branch length 
corresponding to 0.1 changes per residue, and identities were ordered by similarity to 
human a-parvalbumin).31 
 
The structure of the parvalbumin from carp was first determined by Kretsinger and 
Nockolds in 1973 which was the first EF-hand motif described.33 The crystal structure of 
the carp parvalbumin revealed the rather unusual odd number of three calcium-binding EF-
hands. One EF hand (EF1) was found to be non-functional and its α-helices are anti-
parallel. The other two, EF2 and EF3, have approximately perpendicular interhelical 
angles. EF2 and EF3 form a hydrophobic patch into which EF1 is packed.33-35 The allergen 
Gad c 1, the major allergen of the Baltic cod (Gadus callarias), has been purified, 
characterised and its structure has been partially resolved by Aas et al.36 The 12.3 kDa 
parvalbumin Gad c 1 has an isoelectric point of 4.4 and can bind two calcium ions.36 
In 2002 a novel parvalbumin allergen of Atlantic cod (Gadus morhua) was detected with a 
monoclonal anti-parvalbumin antibody in Western blotting of cod protein extract.37 A 
24 kDa IgE-reactive band was found to be a dimer of the Atlantic cod allergen Gad m 1. 
Alignment of the amino acid sequence of the 11.5 kDa protein manifested the typical 
characteristics of β-parvalbumins: calcium-binding sites, a cysteine at position 18, an 
arginine at position 75 and a quadruplet of acidic residues in the region 59-62. The new 
parvalbumin allergen formed oligomers under native as well as under reducing conditions. 
Homology studies showed higher similarity to the allergen Sal s 1 from Atlantic salmon 
(Salmo salar) than Gad c 1 from Baltic cod although the Atlantic cod is phylogenetically 
much closer to the Baltic cod than to the Atlantic salmon.37 
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Allergens are classified as cross-reactive if they share B-cell or T-cell epitopes which is 
based on their structural similarity.38 Cross-reactivity between fish parvalbumins has been 
observed among various species like cod, salmon, pollack, herring, and wolffish. The IgE-
binding patterns were the strongest in phylogenetic closely related species suggesting 
similar IgE epitopes.39 
Investigation of potential IgE epitopes of β-parvalbumin was performed by mutational 
analysis on the major carp allergen Cyp c 1.40 The allergen retained its structure and IgE 
reactivity was only modestly reduced when a single mutation was introduced into one of 
the calcium-binding regions. However, when both calcium-binding sites were mutated, the 
parvalbumin completely lost its conformation and IgE reactivity was reduced about 95%. 
The mutation of only 4 amino acids almost completely abolished its allergenicity and the 
protein was not able to fold correctly which indicates that parvalbumin IgE epitopes are of 
a conformational nature and that the calcium-binding domains are highly relevant.40  
1.1.5 The Pollen-Food Syndrome 
Type I allergic reactions to plant-derived foods are often a consequence of primary 
sensitisation to pollen allergens. This type of food allergy is known as class 2 food 
allergy.21 The so called pollen-food syndrome (PFS) is based on the cross-reactivity of IgE 
antibodies to conserved plant allergens that are expressed in related and unrelated plant 
species and different plant tissues. The panallergens responsible for this reaction comprise 
a limited number of protein families: the actin-binding profilins, pathogenesis-related 10 
(PR-10) plant proteins, polcacins and non-specific lipid transfer proteins (nsLTP).41 The 
non-sensitising allergens in plant foods are also called incomplete food allergens because 
they only provoke allergic reactions in already sensitised patients.42 Generally, these 
incomplete food allergens tend to be labile during heating and digestion 43 and are 
associated with symptoms of the oral allergy syndrome characterised by local symptoms at 
the site of food contact such as itching of the lips, tongue, and throat, sometimes 
accompanied by swelling of the lips and tongue.44 
In Europe, more than 70% of birch pollen allergic patients exhibit type I hypersensitivity 
reactions to pollen-related food allergens such as the apple, hazelnut and celery.45 Major 
allergens responsible for these symptoms belong to a group exhibiting high-level 
homology with Bet v 1, the major allergen of birch pollen. 
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1.1.5.1 The PR-10 protein subfamily 
Pathogenesis related proteins are induced in higher-order plants in response to infections 
by pathogens such as fungi, bacteria or viruses, wounding or the application of chemicals 
that mimic the effect of such an infection or induce similar stresses. The pathogenesis 
related proteins comprise 17 protein families.46 PRs do not constitute a superfamily of 
proteins but represent a collection of unrelated protein families which function as part of 
the plant defence system.47 
 
Table 1.2 Some identified PR-10 related plant food components.48 
 
 
The major birch pollen allergen Bet v 1 is a member of the PR-10 protein subfamily. 
Proteins with high sequence similarity to Bet v 1 have been identified in a wide range of 
flowering plants, some are shown in Table 1.2. Interestingly, the majority of Bet v 1-
homologous food allergens have been found in the fruits of Rosaceae species (e.g. apple, 
pear, cherry, apricot, peach) or in somatic tissues of Apicaeae species (e.g. celery, carrot, 
parsley).47, 49 Most of them cause rather mild clinical syndromes of the OAS because of 
their lability during cooking in some cases. Systemic and more severe reactions can occur 
after ingestion of celery and soybean because of the still allergenic Api g 1 and Gly m 4 
(SAM22) respectively, even after long cooking.50, 51 
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Table 1.3 Data of Bet v 1–related allergenic food proteins with known cDNA sequences.49 
 
 
 
Most genes of the PR-10 group have an open reading frame from 456 to 489 bp encoding 
polypeptides of 151–162 amino acids with molecular masses of 15–18 kDa.52 The 
members shown in Table 1.3 all have theoretical isoelectric points (pI) in the acidic range 
between 4.4 and 6.1. The amino acid sequence identity to Bet v 1 varies between 38% 
(Dau c 1) and 67% (Cor a 1.04). The sometimes rather low sequence identity but very 
similar tertiary fold of these proteins led to the assumption that the IgE cross-reactivity of 
Bet v 1 and its homologues in foods is highly conformation dependent.49 This was 
supported by a recent mutational analysis of Bet v 1.0101 where amino acids 109 to 115 of 
Mal d 1, the Bet v 1 homologue from apple, were transplanted into the Bet v 1 backbone. 
The resulting protein lacked the typical Bet v 1-like fold and its IgE binding capacity was 
dramatically reduced. This led to the speculation that allergenicity of Bet v 1 and Bet v 1-
related proteins is due to their highly conserved fold.53 
1.1.5.2 The major birch pollen allergen Bet v 1 
The X-ray and NMR structural analyses of Bet v 1 revealed a seven stranded anti-parallel 
β-sheet that wraps around a 25 residue-long C-terminal helix. The β-sheet and the C-
terminal part of the long helix are separated by two consecutive α-helices. The most 
remarkable feature of the three-dimensional structure of Bet v 1 is the so called P-loop 
motif which is formed by the cluster of surface-exposed conserved polar residues (glycine 
46, 48, 49 and 51) in close vicinity to its cavity.54 Analyses of antigen-antibody 
interactions on Bet v 1 exhibited the conserved P-loop to be of major importance for IgE 
binding.55 A lot of current work is focused on the investigation of further IgE epitopes on 
Bet v 1 and Bet v 1-related food allergens. 
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Raising antibodies against peptides of Bet v 1 has become a useful tool for mapping of IgE 
epitopes. For the purpose of preventive vaccination, IgG antibodies raised against the 
peptide aa 130-160 of Bet v 1 showed the capability of inhibiting IgE-binding to Bet v 1 
for up to 42%.56 These findings make the Bet v 1 C-terminal helix and its preceding loop 
IgE epitope candidate patches of major importance.56 In another study the use of Bet v 1 
peptide-specific monoclonal antibodies able to strongly inhibit IgE-binding to Bet v 1 
revealed that the surface patches aa 29-58 and aa 73-103 are parts or lie in close vicinity of 
Bet v 1 IgE epitopes.57 
A different experimental approach for the identification of IgE epitopes is to graft Bet v 1 
epitopes onto the surface of Bet v 1 homologous proteins and look for the influence of IgE 
binding patterns. Point mutations in the P-loop region of Mal d 1, the apple homologue of 
Bet v 1, increasing the surface similarity to Bet v 1 resulted in an increase of binding 
capacity of birch pollen allergic serum IgE.58 These findings were also in accordance with 
a previous site-directed mutagenesis study on Bet v 1, identifying the P-loop region and 
surrounding residues as an important IgE epitope patch although its significance seems 
patient specific.59 
Alternatives for the identification of conformational epitopes are in silico studies based on 
structural bioinformatics. The algorithms used for prediction of epitopes usually consider 
features like solvent accessibility, backbone flexibility or hydrophilicity. The combination 
of structural and IgE cross-reactivity data predicted IgE-reactive surface portions in the 
region aa 127-135 of Bet v 1 in agreement with previous IgE epitope mapping studies.56, 60 
1.1.6 Chimeric proteins of Bet v 1 and Api g 1 
The major birch pollen allergen Bet v 1 and its homologue in celery, Api g 1, share only 
40% sequence identity but, nevertheless, their tertiary structure is very similar.61 The major 
differences at the amino acid level are situated between residues 23 to 45 preceding the 
highly conserved glycine-rich P-loop as well as in loops β3- β4 and β5- β6. Furthermore 
Bet v 1 has a five residue extension at the C-terminus 61 and the major celery allergen 
Api g 1 lacks residue E45 which has been shown to be a critical residue for IgE binding.59 
Although IgE cross-reactivity between Api g 1 and Bet v 1 is reported for approximately 
68% of birch pollen sensitised patients and confirmed by double-blind placebo-controlled 
food challenge 62, the entirety of responsible epitopes has yet to be determined. 
The in silico analyses and comparison of Bet v 1 and Api g 1 sequences and structures 
inspired the idea of transplanting four interesting Bet v 1-specific regions onto the 
homologous celery allergen Api g 1. Grafting of surface residues from Bet v 1.0101 onto 
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Api g 1.0101 for the generation of chimeric proteins was done by cloning the DNA 
constructs into the Escherichia coli expression vector pET32a (performed by DI Barbara 
Gepp, Department of Pathophysiology and Allergy Research, Medical University of 
Vienna, Vienna, Austria). 
 
 
Figure 1.4 Amino acid sequence alignment of Api g 1.0101, the chimeric proteins Api-Bet-
1 to Api-Bet-4 and Bet v 1.0101. 
 
The sequence alignment in Figure 1.4 highlights similarities and differences between 
Api g 1.0101, the four chimeric proteins and Bet v 1.0101. For the construction of Api-
Bet-1 the residues T28, K39, K44, D46 and D60 of Api g 1 have been mutated towards 
Bet v 1 and the residue N43 was introduced which corresponds to the region forming the 
P-loop. For Api-Bet-2 the region opposite of the P-loop, for Api-Bet-3 the 5 amino acids 
long C-terminus plus surrounding residues and for Api-Bet-4 the C-terminal α-helix from 
Bet v 1 were grafted onto the scaffold of Api g 1.  
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Figure 1.5 Structural models of Api g 1.0101, Bet v 1.0101 and Api-Bet chimeric proteins 
(green; Api g 1 solvent-accessible residues identical to corresponding ones in Bet v 1, 
yellow; Api g 1 solvent accessible residues different from corresponding ones in Bet v 1, 
blue; residues mutated towards Bet v 1) (by DI Barbara Gepp, Department of 
Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria)). 
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1.2 Monoclonal antibodies 
Most antigens and allergens possess a large number of epitopes that are recognised by 
lymphocytes of the challenged organism. Activated B cells differentiate into antibody-
secreting plasma cells each of which produces antibodies of a single specificity for one 
epitope. Thus, the resulting antibody response to an antigen is polyclonal.1 There is a 
general interest in producing monoclonal antibodies with the specificity for only one 
epitope deriving from one single B cell clone.  
The first revolutionary technique to produce virtually unlimited quantities of monoclonal 
antibodies was developed by Köhler and Milstein in 1975 for which they were awarded 
with the Nobel Prize.63 The method relies on the principle of fusing antibody-secreting 
B cells from the spleen of immunised mice with mutant myeloma cells in order to obtain 
immortal antibody-producing cells. Such fusion-derived cell lines are called hybridomas 
and the antibodies produced by each line are monoclonal antibodies.63 
Antibodies are widely used in research, diagnostic analyses and therapeutic approaches. 
The decision whether to use polyclonal (pAb) or monoclonal antibodies (mAb) depends on 
numerous factors and also on their commercial availability. For some purposes the 
homogeneity and consistency of mAbs may be required but pAbs can be generated much 
more rapidly. Furthermore the production of pAbs is less expensive, requires less technical 
skills and can be carried out in larger amounts than the production of mAbs by the 
hybridoma technology.64 
Although extremely useful, the hybridoma technology is not easily amenable to high 
throughput and is unable to overcome the problems of toxicity or poor immunogenicity. 
The development of new recombinant technologies that involve antibody display on the 
surface of bacteriophage, bacteria, yeast, ribosome or puromycin have simplified the 
generation of monoclonal antibodies. Table 1.4 describes the elementary steps in this 
technology.65 
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Table 1.4 Key elements in antibody display technologies.65 
 
Step Feature 
1 Generation of diversity at the nucleic acid level to create the library, usually 
of binding ligands. For example, natural or synthetic V genes, V genes with 
mutations. 
2 Coupling of genotype and phenotype, alternatively translated protein with 
encoding gene, or information and function. This is done using living 
organisms or in vitro methods. 
3 Application of selective pressure, for example binding to a specific target. 
4 Amplification of selected clones by growth, infection or PCR. 
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1.3 Antibody phage display technology 
The core technology behind recombinant monoclonal antibodies is antibody phage display 
with an important role in the development of diagnostic and therapeutic reagents. The 
hallmark of this method is the coupling of an antibody’s genetic information to its 
phenotype as depicted in step 2 of Table 1.4. Phage display libraries can be created from 
different sources. They are classified as constructed from B cells of immunised (Fig. 
1.6 A) or non-immunised organisms (Fig. 1.6 B) or from an artificial repertoire (Fig. 
1.6 C).66 
 
 
Figure 1.6 Overview of recombinant monoclonal antibody technologies (A; B; C; different 
types of sources).66 
 
In type C of antibody phage display technology (Fig. 1.6) the V-gene and D/J segments are 
assembled in vitro by using PCR in order to by-pass immunisation. A repertoire of human 
heavy chain variable region (VH) and light chain variable region (VL) germline encoded 
genes can hereby be rearranged and randomised to create highly diverse libraries.67 Most 
phage display libraries use the filamentous phage strain M13 as vector.68 The foreign 
cDNA is cloned into the gene for one of the phage coat proteins, g3 or g8. As fusion of 
peptides larger than 8 amino acids to the coat protein pVIII, which is present in 
approximately 2700 copies, will not support phage production without additional effort, 
fusion of the antibody to the minor coat protein pIII (5 copies) is preferred.69 As the 
foreign cDNA is inserted directly into the phage genome, any disruption of pIII or pVIII 
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function makes the phage not viable and the fused protein will not be displayed. To 
overcome this problem the use of helper phages in addition to phagemids was introduced. 
In this case, the phagemid particle carries only the foreign cDNA inserted into the coat 
protein genes gIII or gVIII. Phages are then generated by infecting the host cells with a 
M13 helper phage strain with all the genes necessary for phage production.70 By using a 
helper phage that contains a slightly defective origin of replication such as M13K07 or 
VCS-M13, the phagemid encoding the protein-pIII or pVIII is packaged preferentially. The 
phage particles either incorporate the coat protein from the helper phage or the fusion 
protein derived from the phagemid. For pIII, approximately one of the five copies, and for 
pVIII from 1% to 30% of the 2700 copies, will display the foreign protein.71, 72 
Two antibody phage display systems which differ in the number of antibody domains 
expressed and in the way of linkage can be used. Antibody fragment (Fab) systems display 
the two light chain domains, variable and constant, as well as the variable and first constant 
domain of the heavy chain (Fig. 1.7 B). For single-chain variable domain (scFv) systems 
only the variable domains of each chain are present attached by a polypeptide linker (Fig. 
1.7 C).71 
 
 
Figure 1.7 Structure of human IgG (A), Fab fragment (B) and single chain variable 
fragment scFv (C).73 
 
Although Fab antibody fragments contain more of the native antibody structure and may 
be a better representative, recombinant scFv are more stable because the smaller size of the 
foreign gene inserted into the vector.71 
Once phages displaying the desired antibody fragments are produced, a selection process 
for the isolation of specific clones by the application of some kind of pressure has to be 
performed. This step is accomplished by a process called biopanning or sequential antigen 
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panning (SAP) where phages displaying antibody fragments can be physically isolated by 
binding to the antigen.74 
 
 
Figure 1.8 Schematic representation of one panning and amplification cycle.75 
 
Figure 1.8 shows how phages are selected from an antibody phage display library. Phages 
displaying the antibody with the desired binding specificity remain bound to the 
immobilised antigen whereas unspecific phages are eluted. After elution of the antigen-
specific phages they can be amplified by growth in host strains and successive rounds of 
panning. Even rare binding specificities in the pool of a large repertoire can be selected and 
amplified by sequential antigen panning. After isolation, monoclonal antibody fragments 
can be produced.75 
1.3.1 The ETH-2 synthetic human scFv antibody library 
The ETH-2 library is a phage display library of human recombinant antibodies in the scFv 
format and a modified version of the synthetic antibody library of Pini et al.74 The scFv 
antibodies are displayed as pIII fusions and have a diversity of approximately 3x108. Only 
three antibody germline segments were used for cloning of the antibodies onto which short 
variable complementary-determining regions 3 (CDR3) were appended.76 The heavy chain 
variable domain consists of the constant DP-47 germline gene with an appended random 
loop of 4, 5, or 6 amino acids. The heavy chain sequence then continues with a constant 
segment and a polypeptide linker connecting it to the light chains as shown in Figure 1.9.75 
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Figure 1.9 Design of the ETH-2 antibody phage display library (amino acids are indicated 
in the single letter code; X, random residue).75 
 
For the design of the light chain variable domain two germline gene segments were used. 
The sequences of DPK-22 and DPL-16 are depicted in Figure 1.9. Each light chain 
variable domain is composed of one of these germline segments and a partially 
degenerated CDR3 which can be paired to the VH domain due to the polypeptide linker.75 
The scFv library inserts were then cloned into the phagemid vector pDN332 a derivative of 
the phagemid pHEN1.77 The vector has two origins of replication, one for packaging into 
phage particles (M13 ori) and one for replication in the E. coli host strain (colE1 ori). The 
ampicilin resistance serves as selection marker, the pelB leader sequence directs the pIII-
fusion-protein to the periplasm of the bacteria and the lacZ-promoter allows protein 
expression control with induction by IPTG and inhibition by glucose.76 The amber stop 
codon between the tag and the gIII sequence gives the possibility of either expressing the 
scFv antibody fused to the pIII coat protein when infecting an E. coli suppressor strain like 
TG1 or to express it as a soluble protein when infecting an E. coli non-suppressor strain 
like HB2151 (Fig. 1.10).78 
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Figure 1.10 Schematic representation of the ETH-2 library ligated into the phagemid 
vector pDN332.78 
 
The D3SD3-FLAG-HIS6 tag appended at the C-terminal end of the recombinant scFv 
additionally provides a FLAG and (His)6 sequence which can be utilised for detection or 
purification and a phosphorylation site for labelling with radioactive 32P.76 
Synthetic phage libraries have the advantage that the characteristics of the displayed 
antibody like its structure, constant and variable regions are defined a priori.75 Further 
benefits are that the library is not biased against self-antigens and the possibility of 
specifically randomising amino acid residues known to be important for antigen binding.79 
It is anticipated that by exploiting the potential of the antibody phage display technology 
the development of antibody reagents important for research, diagnostic tools and therapy 
will become an inexpensive, powerful, fast and routine method for antibody engineering.66 
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1.4 Objectives 
1.4.1 Chapter 1: Expression and purification of the parvalbumin specific single-
chain variable fragment antibody scFv-K/F9 and the isotope-labelled 
parvalbumin rGad m 1.02 
Although fish allergy is associated with IgE-mediated hypersensitivity to the almost 
exclusive allergen parvalbumin, its structure in many fish species remains to be resolved.80 
This is also true for the major allergen of the Atlantic cod (Gadus morhua), Gad m 1, 
which was initially described in 2002 by Das Dores et al.37 The aim of this study was to 
develop and optimise a protocol for the expression of the recombinant isotope-labelled 
rGad m 1.02 in order to obtain the purified protein. Moreover the expression and 
purification of a parvalbumin-specific scFv antibody, scFv-K/F9, had to be accomplished. 
Both the isotope-labelled rGad m 1.02 and the purified scFv-K/F9 were provided for NMR 
spectroscopy to Prof. Ana Paula Valente at the Federal University of Rio de Janeiro, 
Brazil, with the purpose of resolving the parvalbumin’s structure and to identify the 
epitope of the scFv-K/F9. The interest in locating the antibody’s epitope on the surface of 
rGad m 1 was aroused because of its ability to inhibit sIgE binding to rGad m 1 in the sera 
of fish allergic patients.81 
1.4.2 Chapter 2: Isolation of recombinant scFv antibodies against the major birch 
pollen allergen Bet v 1 and its homologues in plant foods 
The technology of antibody phage display provides a method for rapid selection of single 
chain variable fragment antibodies specific for any antigen of choice. It allows the 
selection of human recombinant monoclonal antibodies without the limitations 
encountered in the use of polyclonal antibodies and hybridoma technology. The application 
of scFv antibodies for allergen research and detection, diagnosis and therapy of 
hypersensitivity diseases is of general interest. The aim of this part of the study was the 
isolation of scFv antibodies specific for the major birch pollen Bet v 1 and its homologues 
in plant foods from the ETH-2 library. The characterisation of the isolated antibodies by 
various enzyme-linked immunosorbent assays was of main prominence. Another matter of 
interest was the ability of the selected antibodies to inhibit sIgE binding to Bet v 1 in sera 
of birch pollen allergic patients. 
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2 Materials and Methods 
2.1 Materials 
Table 2.1 Chemicals and suppliers. 
 
Chemicals  Supplier 
L-glutamine Biochrom AG, Berlin, Germany 
4-Nitro blue tetrazodium chloride (NBT) 
5-Bromo-4-chloro-3-indolyl-phosphate (BCIP) 
ß-Mercaptoethanol 
Boric acid 
Coomassie Brilliant Blue R-250 (CBB) 
Dithiothreitol (DTT) 
D(+)-Sucrose 
Glycine 
Tris(hydroxymethyl)aminomethane 
Tris(hydroxymethyl)aminomethane, Ultra Pure 
Triton-X100 
Biomol GmbH, Hamburg, Germany
Agar 
Ampicillin sodium salt (Amp) 
Bis-Tris 
Bovine serum albumin (BSA) 
Ethylene diamine tetraacetic acid (EDTA) 
Glycerol ≥ 99.5%, p.a. waterfree 
Hepes 
Imidazole 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
Kanamycin sulfate (Kan) 
Milk powder 
N,N,N,N-tetramethylethylenediamine (TEMED) 
Polyethylene glycol (PEG) 6000 
Sodium dodecyl sulphate (SDS) 
Carl Roth GmbH and CO. KG, 
Karlsruhe, Germany 
Human IgE (1mg·mL-1) 
α-human IgE monoclonal antibody 
Diatec AS, Oslo, Norway 
Ammoniumperoxidisulfate (APS) Gibco BRL, MD, USA 
Foetal calf serum (FCS) 
Geneticin sulphate (G-418) 
Minimum essential media (MEM) 
Invitrogen Corporation, Carlsbad, 
CA, USA 
Acetic acid  
Acrylamide 
Ammonium sulphate 
Bis-acrylamide 
Bromphenol blue 
CaCl2·2H2O 
D(+)-Glucose monohydrate 
Ethanol 
Ethidium bromide (EtBr) 
Isopropanol 
Merck, KGaA, Darmstadt, 
Germany 
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KCl 
KH2PO4 
Methanol 
MgCl2·6H2O 
MgSO4·7H2O 
NaCl 
NaHCO3 
Na2HPO4·2H2O 
NaH2PO4·H2O 
NaN3 
NaOH 
NH4Cl 
Peptone 
Tetracycline (Tet) 
Yeast extract 
Complete EDTA-free Protease Inhibitor Cocktail 
Tablets 
Roche Diagnostics GmbH, 
Mannheim, Germany 
Chloramphenicol (Cam) 
Citric acid 
Deuterium oxide (D2O) 
HCl 
PolyVinylPolyPyrrolidone (PVPP) 
p-Nitro-N-acetyl-β-D-glucosaminide 
p-Nitrophenyl phosphate (pNPP) tablets 
Streptomycin (Strep) 
Triethylamine 
Tween 20 
Sigma-Aldrich Co., St.Louis, MO, 
USA  
MATERIALS AND METHODS 
 27
2.2 Methods 
2.2.1 Expression of rGad m 1 using the pET17b expression vector 
The pET17b expression vector (Novagen, Madison, WI) was used for expression of the 
recombinant β-parvalbumin of the Atlantic cod in four different E. coli strains. Therefore, 
the cDNA coding for Gad m 1.02 (accession A5I874) was inserted into the HindIII/BamHI 
restriction sites of pET17b expression vector.27 This put the target gene under the control 
of the T7 polymerase and the host cell has to be genetically engineered to incorporate the 
gene for the lac promoter, the lac operator and the T7 RNA polymerase in its genome. This 
makes the host cell able to provide a source for the T7 RNA polymerase under the control 
of lactose or isopropyl β-D-1-thiogalactopyranoside (IPTG) induction. IPTG is preferred 
as an inducer because unlike lactose it cannot be metabolised by E. coli, its concentration 
remains constant and the expression rate of the induced target gene is equal throughout 
the experiment.82, 83 The expression of rGad m 1 was performed in four E. coli strains each 
of which fulfils the requirements above: BL21(DE3) (genotype: F– ompT hsdSB (rB– mB–) 
gal dcm (DE3)), BL21-Codon Plus(DE3)-RIPL (genotype: F– ompT hsdS(rB– mB–) dcm+ 
Tetr gal λ(DE3) endA Hte [argU ileY leuW Strep/Specr]), Tuner-(DE3)-pLacI (genotype: 
F– ompT hsdSB (rB– mB–) gal dcm lacY1(DE3) pLacI (CamR)) and Rosetta-gami 
2(DE3)pLysS (genotype: Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE 
galK rpsL (DE3) F′[lac+ lacIq pro] gor522::Tn10 trxB pLysSRARE2 (CamR, StrR, TetR)).  
2.2.1.1 Transformation of E. coli BL21(DE3), BL21-Codon Plus(DE3)-RIPL, Tuner-
(DE3)-pLacI and Rosetta-gami 2(DE3)pLysS 
The chemical competent E. coli strains BL21(DE3) (Novagen, Madison, WI), BL21-Codon 
Plus(DE3)-RIPL (Stratagene, La Jolla, CA), Tuner-(DE3)-pLacI (Merck, Darmstadt, 
Germany) and Rosetta-gami 2(DE3)pLysS (Novagen, Madison, WI) were transformed with 
the expression vector pET17b harbouring the Gad m 1.02 cDNA. 
Procedure: 
For each transformation reaction an aliquot of 100 µL of the respective chemical 
competent cells was thawed on ice and incubated with 50 ng DNA of the expression vector 
for 15 min on ice. Afterwards the cells were heat shocked at 42°C for 45 sec in a water 
bath and immediately replaced on ice for 5 min. After adding 300 µL of SOC medium to 
each sample, the cells were incubated for 1 h at 37°C with gentle shaking. Two LB plates 
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per transformation reaction with the appropriate antibiotics listed in Table 2.2 were pre-
warmed at 37°C. 
 
Table 2.2 Listing of bacterial strains and antibiotic resistances. 
 
E. coli strain LB-antibiotic plate 
BL21(DE3) LB-Amp 
BL21-Codon Plus(DE3)-RIPL LB-Amp-Cam-Strep 
Tuner-(DE3)-pLacI LB-Amp 
Rosetta-gami 2(DE3)pLysS LB-Amp-Cam-Tet 
 
First, 20 µL of the transformed cells were plated, the rest was centrifuged for 2 min at 
13,200 rpm, the pellet was carefully resuspended in 100 µL of the supernatant and the total 
volume was plated and incubated o/n at 37°C. 
Buffers and reagents: 
SOC medium: 
 Peptone   2% 
Yeast extract   0.5% 
NaCl    10 mM 
KCl    2.5 mM 
MgCl2·6 H2O   10 mM 
MgSO4·7 H2O  10 mM 
Glucose   20 mM 
 dissolved in ddH2O and autoclaved 
LB medium: 
Peptone   1% 
Yeast extract   0.5% 
NaCl    1% 
for plates add 15 g·L-1 of Agar 
pH 7.5 adjusted with NaOH and autoclaved 
Ampicillin (Amp): 
 Stock solution: 100 mg·mL-1 in ddH2O 
 use 1:1000 for media and plates 
 
 
MATERIALS AND METHODS 
 29
Chloramphenicol (Cam): 
 Stock solution: 20 mg·mL-1 in 100% ethanol 
 use 1:1000 for media and plates 
Streptomycin (Strep): 
Stock solution: 20 mg·mL-1 in ddH2O 
use 1:1000 for media and plates 
Tetracycline (Tet): 
 Stock solution: 20 mg·mL-1 in 70% ethanol 
use 1:1000 for media and plates 
2.2.1.2 Optimising protein expression under controlled conditions 
After o/n incubation E. coli clones of each transformation assay were picked for long 
storage bacterial stocks and for the expression of rGad m 1. As the optimal conditions for 
the expression of this β-parvalbumin were not known at this point, several attempts were 
carried out varying the growth media, the expression period and the point of time of IPTG 
induction. For all trials M9 minimal medium and/or E. Coli-OD2 unlabelled medium 
(Silantes GmbH, Munich, Germany) were inoculated with o/n cultures of the transformed 
E. coli BL21(DE3), BL21-Codon Plus(DE3)-RIPL, Tuner-(DE3)-pLacI and Rosetta-gami 
2(DE3)pLysS (1:100 dilution) and grown at 37°C with agitation until a bacterial cell 
density OD600 of 0.4-0.5 was reached (U-1800 Spectrophotometer, Hitachi Ltd., Tokyo, 
Japan). Protein expression was then induced in one half of the bacterial cultures by 1 mM 
IPTG. Expression levels of rGad m 1 were monitored by incubating all the cultures o/n at 
37°C with agitation and taking samples at different points of time (3, 6 and 24 h). The 
expression levels of rGad m 1 were analysed by sodium dodecylsulfate (SDS) 
polyacrylamide gel electrophoresis (see section 2.2.6). 
2.2.1.3 Expression of isotope-labelled rGad m 1 
In order to perform NMR spectroscopy, the protein to be analysed has to be isotope-
labelled. After optimisation of the expression protocol in unlabelled medium, the E. coli 
strain BL21(DE3) was chosen. For protein NMR analysis, the isotope labels are 
introduced by growing the bacteria in a specific medium which is based on the recipe of a 
minimal medium containing carbon (13C) and nitrogen (15N) sources.84 
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Procedure: 
One liter of E. Coli-OD2 CN medium (Silantes GmbH, Munich, Germany) was inoculated 
with a transformed E. coli BL21(DE3) o/n culture (1:100 dilution) and grown at 37°C with 
gentle shaking until an OD600 0.4 was reached. The rGad m 1 expression was induced by 
adding 1 mM IPTG and bacterial growth was continued o/n at 37° C.  
2.2.1.4 Preparation of bacterial cell extract using a French Pressure Cell Press 
To prepare protein extracts from bacteria the cell wall has to be disrupted. The French 
Pressure Cell Press is an efficient mechanical method which results in a uniform and 
complete disruption of cell membranes and cell walls. Bacterial samples are placed into 
the French Pressure cell and pressurised. When cells and organelles pass the outlet valve 
the external pressure drops rapidly whereas the cell’s internal pressure is still extremely 
high. The pressure differential causes cells and organelles to burst. The resulting 
homogenous solution needs to be centrifuged to separate the cell extract from cell wall 
fragments.85 
Procedure: 
One litre bacterial culture was centrifuged (7,000 rpm, 30 min, 18°C) and the pellet was 
resuspended in 10 mL 20 mM sodium-phosphate buffer, 1 mM EDTA, 5 mM DTT, pH 
7.5. Before pouring the sample into the French Pressure Cell Press (SLM Aminco, 
Rochester, NY) a Complete EDTA-free Protease Inhibitor Cocktail tablet was added. The 
piston and the cell were assembled according to the user’s manual and the pressure cell 
was filled with the E. coli cell suspension. The filled pressure cell was placed onto the 
lower platen of the French Press and secured with the cell clamp. The lower platen was 
lifted which pushed the handle into the cell body. When the movement stopped, the 
pressure was increased up to 1,000 psi and the outlet valve was slightly opened. The liquid 
flow-out was collected until the piston reached the “Stop” sign. The outlet valve was 
opened completely to release any remaining pressure and the pressure cell was brought 
into starting position. The components were disassembled and the process was repeated 
three times to obtain a homogenous cell lysate.  
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Figure 2.1 French Pressure Cell Press components (SLM Aminco, Rochester, NY). 
2.2.2 Dialysis 
For desalting samples or changing the buffer, dialysis is an easy and inexpensive but time-
consuming method. The sample and the exchange buffer are placed at opposite sites of the 
membrane. By choosing dialysis tubes with the appropriate size of membrane pores, 
sample molecules that are larger than the pores are retained whereas smaller molecules 
such as salts can diffuse freely through the membrane. In order to achieve high dialysis 
performance a ratio of at least 1:100 of sample to buffer is required and the process 
should be carried out o/n with gentle stirring. 
Procedure: 
After resuspending the pellet, the protein sample was dialysed against 20 mM Bis-Tris-
HCl pH 6.5 in a membrane tube (Spectra/Por6 molecularporous membrane, Spectrum, 
Rancho Dominguez, CA) MWCO 1,000. Dialysis was performed o/n at 4°C with gentle 
stirring. After desalting, the protein sample was ready for ion exchange chromatography.  
2.2.3 Protein purification methods 
2.2.3.1 Precipitation with polyethylene glycol 
Polyethylene glycol (PEG) is a non-toxic water soluble synthetic polymer of ethylene oxide 
and is available over a wide range of molecular weights. The protein precipitation process 
with PEG is due primarily to excluded volume effects and the removal of the shell of 
hydrating water. When the synthetic polymer is added to a solvent, it occupies a large 
volume from which proteins get excluded. They thus concentrate until their solubility is 
exceeded and precipitation of the proteins occurs. Protein precipitation and purification 
however is very protein specific and thus needs individual protocol optimisation.86, 87 
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Procedure: 
The obtained homogenous cell lysate from the French Pressure Cell Press was pelleted 
(15,000 rpm, 1 h, 4°C) and the supernatant was collected. Polythylene glycol precipitation 
was performed by adding 1/10 volume of a 20% PEG6000, 2.5 M NaCl solution and gently 
inverting the reaction mix. After 45 min incubation on ice the cloudy solution was 
centrifuged (13,000 rpm, 20 min, 4°C) and the pellet was dissolved in 20 mM sodium-
phosphate buffer, pH 7.5. After each step a sample was taken for analysis by SDS-PAGE 
and Western Blotting. In order to perform ion exchange chromatography for further protein 
purification, the protein solution needed to be desalted by dialysis (see section 2.2.2).  
2.2.3.2 Ion exchange chromatography 
Ion exchange chromatography (IEX) is based on the interaction between charged solute 
molecules and oppositely charged molecules immobilised on a chromatography matrix. A 
distinction is made between anion and cation exchange columns depending on the charge 
of the covalently linked molecule on the matrix. The net surface charge of a protein varies 
depending on the surrounding pH. In an environment above its isoelectric point (pI) a 
protein will bind to an anion exchanger, when below its pI it will bind to a cation 
exchanger. The elution is usually accomplished by changing to conditions unfavourable for 
ionic bonding, this is done by increasing salt concentration or changing the pH. IEX is 
probably the most frequently used chromatographic technique for the separation and 
purification of proteins, nucleic acids, polynucleotides and other charged biomolecules. It 
is characterised by its simplicity, high capacity and high resolving power. IEX usually 
involves five steps: equilibration of the ion exchanger to starting conditions, sample 
application and binding, washing of unbound substances, elution of adsorbed molecules 
and re-equilibration followed by regeneration for the next purification experiment.88 
2.2.3.2.1 Anion exchanger: Q Sepharose Fast Flow 
Procedure: 
Protein purification by IEX was performed with a Pharmacia fast performance liquid 
chromatography (FPLC) system (GE Healthcare, Little Chalfont, UK). The column matrix 
used was a Q Sepharose Fast Flow (GE Healthcare, Little Chalfont, UK), a strong anion 
exchanger which uses a quaternary amine group as ion exchange group and highly cross-
linked agarose for the base matrix. The sample and all buffers were filtered before 
application. The column was equilibrated with binding buffer (low ionic strength) and 
loaded with the counter-ion by changing to elution buffer (high ionic strength). Unbound 
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counter-ions were washed out with binding buffer until the starting state was reached. The 
protein sample was loaded onto the column at a flow rate of 1 mL·min-1. After washing 
with binding buffer, bound proteins were eluted by a linear gradient from 0-50% of elution 
buffer at a flow rate of 1 mL·min-1 and collected in 1 mL fractions. The elution was 
monitored by a single path monitor UV-1 (GE Healthcare, Little Chalfont, UK) at 280 nm. 
Fractions were analysed by SDS-PAGE. The column was cleaned with 100% of elution 
buffer and re-equilibrated with binding buffer. After washing the column with MiliQ water 
it was stored in degassed 20% ethanol at 4°C.  
Buffers and reagents: 
Binding buffer: 
 Bis-Tris  20 mM 
 adjust pH with HCl to 6.5 
Elution buffer: 
 Bis-Tris  20 mM 
 NaCl  1 M 
 adjust pH with HCl to 6.5 
2.2.3.2.2 Anion exchanger: HiTrap Capto Q 
Procedure: 
The same protocol as in the previous section was followed for the most part. The pre-
packed IEX column used was a 1 mL HiTrap Capto Q column (GE Healthcare, Little 
Chalfont, UK), a strong quaternary ammonium anion exchanger coupled to a chemically 
modified high-flow agarose matrix. After elution with 100% elution buffer, the column 
was cleaned for prospective use according to the user’s manual. This included washing 
with two column volumes of 2 M NaCl followed by 2 washing steps with 4 column 
volumes of 1 M NaOH and 2 column volumes of 2 M NaCl respectively. The IEX column 
was then again equilibrated with 5 column volumes of binding buffer, washed with MiliQ 
water and finally stored in 20% degassed ethanol at room temperature (RT). 
Buffers and reagents: 
Binding buffer: 
 Tris-HCl 20 mM, pH 8.5 
Elution buffer: 
 Tris-HCl 20 mM, pH 8.5 
 NaCl  1 M 
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2.2.3.3 Gel filtration chromatography 
Gel filtration chromatography separates solute molecules according to their size and is the 
simplest and mildest of all the chromatography techniques. Unlike IEX e.g. molecules do 
not bind to the column matrix as it is made of porous spherical particles. Solute molecules 
relatively small compared to the matrix pores can diffuse into the gel from the surrounding 
buffer and are retained whereas relatively large molecules are prevented to diffuse into the 
gel and thus are eluted first. Molecules which partially diffuse into the gel elute from the 
column in order of decreasing size. Small molecules such as salts which fully diffuse into 
the gel pores do not separate from each other and elute when one total column volume of 
buffer has passed through the gel filtration column. One big advantage of gel filtration 
chromatography is that samples are eluted isocratically which means that there is no need 
to use different buffers during the separation.89 
Procedure: 
Gel filtration chromatography was performed using a HiLoad 16/20 Superdex 200 prep 
grade column (GE Healthcare, Little Chalfont, UK) in the same system as described in 
section 2.2.3.1 and monitored at 280 nm. As sample volume should not exceed 5 mL the 
protein solution was concentrated using Centriprep Centrifugal filter units MWCO 3,000 
(Millipore, Billerica, MA). Before applying the sample, the column was equilibrated with 
elution buffer until a stable UV baseline was reached. Solute molecules were separated by 
passing one column volume of elution buffer through the gel filtration column and 
collected in 5 mL fractions. The collected fractions were analysed by SDS-PAGE (see 
section 2.2.6). After gel filtration chromatography the column was washed with MiliQ 
water and stored in 20% degassed ethanol at RT.  
Buffers and reagents: 
Elution buffer: 
 Sodium-phosphate buffer 50 mM, pH 7.4 
 NaCl    150 mM  
2.2.3.4 Affinity chromatography 
Affinity chromatography is based on the reversible interaction between a protein and an 
immobilised ligand coupled to a chromatographic matrix. It allows the purification of 
biomolecules according to their biological function or individual chemical structure. The 
interactions between ligand and the protein to be purified can be of electrostatic or 
hydrophobic nature, van der Waals forces or hydrogen bonding. While the protein of 
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interest is retained, unbound contaminations can simply be washed out. Elution of the 
target protein can either be accomplished specifically by using a competitive ligand or 
non-specifically by varying the pH, ionic strength or polarity. Different kinds of biological 
interactions are used in affinity chromatography such as enzyme-substrate, antibody-
antigen, hormone-receptor or metal ions-poly His protein interactions.90 
2.2.3.4.1 Nickel-based affinity chromatography: HisTrap FF crude column 
Immobilised metal affinity chromatography (IMAC) based on nickel-ions is widely used for 
purifying histidine-tagged proteins. HisTrap FF crude columns (GE Healthcare, Little 
Chalfont, UK) are prepacked with Ni Sepharose 6 Fast Flow, a pre-charged IMAC 
medium with low nickel ion leakage which can be regenerated after use. The nickel ions 
retain proteins when histidine residues are exposed on the surface of the proteins. For 
selective purification of poly-Histidine tagged proteins it is therefore recommended to add 
low concentrations of imidazole to the binding buffer to minimise binding of unwanted 
proteins.  
Procedure: 
The column loaded with nickel ions was equilibrated with binding buffer. The sample was 
loaded with 1 mL·min-1 flow rate and unbound molecules were washed out with sufficient 
volume of binding buffer. The elution of bound proteins was performed with a stepwise 
gradient (10, 20, 50 and 100%) of elution buffer at a flow rate of 1 mL·min-1. Fractions 
were collected according to UV absorption peaks and analysed by SDS-PAGE. After 
IMAC the column was washed with MiliQ water, re-loaded with 100 mM NiSO4 and 
stored in 20% degassed ethanol at RT. 
Buffers and reagents: 
Binding buffer: 
 Sodium-phosphate buffer 50 mM, pH 7.5 
 NaCl    300 mM 
 Imidazole   10 mM 
Elution buffer: 
 = binding buffer + 250 mM imidazole 
 
 
 
 
MATERIALS AND METHODS 
 36 
2.2.3.4.2 Nickel-based affinity chromatography: Ni-NTA spin column 
The principle of Ni-NTA spin columns (QIAGEN GmbH, Hilden, Germany) is as in every 
IMAC chromatography based on immobilised nickel ions which in this special case are 
tightly bound to a nitriltrioacetic acid (NTA) resin. The NiNTA spin kits provide a rapid 
method for screening of histidine tagged proteins from small-scale expression cultures. 
Procedure: 
The manufacturer’s protocol for protein purification under native conditions from E. coli 
lysates was followed. The Ni-NTA spin columns were equilibrated with 600 µL of binding 
buffer and centrifuged (890 g, 2 min, RT). The cell lysate (S1 and S2 pool after 
periplasmatic protein extraction, see section 2.2.5) was loaded and bound to the columns 
by centrifugation (890 g, 2 min, RT). Two washing steps with 600 µL of binding buffer 
and subsequent spinning (890 g, 2 min, RT) were performed. Two elution steps with 300 
µL of 50% elution buffer and 300 µL 100% elution buffer respectively were carried out by 
spinning the columns (890 g, 2 min, RT). A sample of each step during chromatography 
was taken for analysis by SDS-PAGE (see section 2.2.6). 
Buffers and reagents: 
Binding buffer: 
 Sodium-phosphate buffer 50 mM, pH 8 
 NaCl    300 mM 
 Imidazole   10 mM 
Elution buffer: 
 = binding buffer + 250 mM imidazole 
2.2.3.5 Immunoprecipitation of FLAG-tagged proteins 
The technique of immunoprecipitation (IP) uses the interaction between an antibody and 
its antigen for affinity purification, identification of specific antigens and quantitative and 
qualitative assays of specific antigens. Either polyclonal or monoclonal antibodies from 
various animal species can be used in IP protocols, depending on the experimenter’s aims. 
Antibodies can be bound non-covalently to immunoadsorbents or can be coupled to a 
solid-phase matrix. After solubilising, the antigen is applied to the immobilised antibody 
and gets tightly bound to it. The antibody-antigen complex is precipitated, unwanted 
contaminations are washed out and the antigen is eluted either by a competitive antibody 
ligand or by switching to conditions unfavourable for antibody-antigen interaction.91 
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Procedure: 
A FLAG immunoprecipitation kit (Sigma-Aldrich Co., St.Louis, MO) was used for the 
purification of FLAG-tagged scFv antibodies. The FLAG epitope system relies on the 
small FLAG octapeptide which allows fusion proteins to retain their original conformation 
and function. The IP was performed with anti-FLAG-M2 affinity gel (Sigma-Aldrich Co., 
St.Louis, MO) which is a highly specific monoclonal antibody covalently attached to 
agarose resin. Per 1 mL protein sample 40 µL of gel suspension was transferred in a test 
tube. The resin was centrifuged (8,000 g, 30 sec, RT) and the supernatant was carefully 
discarded. The packed gel was washed five times with 0.5 mL of 1x wash buffer. The 
protein sample was incubated o/n at 4°C on a spinning wheel with the resin. Centrifugation 
(8,000 g, 30 sec, RT) precipitated the resin-protein complex. After removing the 
supernatant, the affinity gel was washed three times with 0.5 mL 1x wash buffer. The 
elution of bound scFv antibodies was performed by competition with 3x FLAG peptide. A 
3x FLAG elution buffer (c3xFLAG peptide=150 ng·µL-1 in 1x wash buffer) was prepared and 
100 µL were added to the resin in the test tube. The samples were incubated with gentle 
shaking for 30 min at 4°C. The resin was centrifuged (8,000 g, 30 sec, RT) leaving the 
eluted scFv antibodies in the supernatant. The whole elution step was performed a second 
time to improve retrieval of the scFv. Each step of IP was monitored by taking samples for 
SDS-PAGE analysis (see section 2.2.6). Protein concentration was determined by BCA 
protein assay (see section 2.2.9.1). 
Buffers and reagents (Sigma-Aldrich Co., St.Louis, MO): 
10x wash buffer: 
 Tris-HCl  0.5 M, pH 7.4 
 NaCl   1.5 M 
3x FLAG peptide solution: 
 3x FLAG peptide 1 mg 
 dissolve in 40 µL 10x wash buffer and 160 µL ddH2O 
 final concentration c = 5 µg·µL-1 
2.2.4 Expression of the parvalbumin specific scFv-K/F9  
An scFv antibody specific for the β-parvalbumin from the Atlantic cod Gadus morhua, 
Gad m 1, was isolated from the phage display library ETH-2 (ETH, Swiss Federal Institute 
of Technology, Zurich) using sequential antigen panning (provided by Maria Kostadinova, 
Department of Pathophysiology and Allergy Research, Medical University of Vienna, 
Vienna, Austria). The phagemid vector pDN332 was used to clone the phage display 
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library ETH-2 which allows producing the antibody either fused to the coat protein III of 
the phage or to produce soluble antibodies in the periplasm of the host. This is achieved by 
either using an E. coli suppressor strain (supE), for examp le TG1, or a non-suppressor 
strain such as HB2151 as a host strain, respectively.75 
2.2.4.1 Transformation of E. coli HB2151  
The chemically competent E. coli HB2151 cells were transformed with the scFv-K/F9-
pDN332 vector. Positive clones were selected by plating the transformed cells on LB-Amp 
plates. 
Procedure: 
The transformation protocol as described in section 2.2.1.1 was followed. Ten clones were 
chosen for PCR colony screening.  
2.2.4.2 PCR colony screening and preparation of bacterial stocks 
Colony screening through polymerase chain reaction (PCR) is a fast method to check 
whether a certain clone carries the desired DNA insert without the need to perform a 
plasmid preparation. The PCR is an in vitro method which uses repeated cycles of 
oligonucleotide-directed DNA synthesis to get exponential accumulation of the target 
sequence. Each cycle consists of three steps comprising the denaturation of the template, 
the annealing of the oligonucleotide primers and an extension reaction in which the 
annealed primers are extended by a thermostable DNA polymerase. At the end of every 
cycle the amount of the target sequence is theoretically doubled. In practice however, 
exponential amplification is only true in the initial cycles and becomes less effective in 
later cycles. By choosing oligonucleotide primers complimentary to their annealing sites 
within the two different strands of the target sequence, only amplification of transformed 
clones will result in the accumulation of the specific DNA fragment.92 
Procedure: 
Each of the ten clones was picked with a sterile pipette tip from the o/n LB-Amp plate and 
transferred to a PCR tube containing 10 µL sterile H2O. The same tip was used to inoculate 
3 mL LB-Amp. The cultures where incubated at 37°C and a bacterial stock was prepared 
by adding 400 µL of glycerine to 600 µL o/n culture and storing the stocks at -20°C. For 
the PCR, a master mix for all samples was prepared relying on the reaction mix for one 
sample. Sterile H2O was used as a negative and 70 ng of the scFv-K/F9-pDN332 vector 
DNA as a positive control. The PCR was performed using a Primus 96 Plus thermal cycler 
(MWG Biotech, High Point, NC). 
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Figure 2.2 scFv-pDN332 map and complementary oligonucleotide primers.76 
PCR cycling program: 
 95°C  10 min  1 cycle 
 95°C  30 sec 
 50°C  30 sec  35 cycles 
 72°C  1 min 
 4°C  ∞ 
 
Buffers and reagents: 
Oligonucleotide primers: 
forward primer c:  DP47CDR2back (MWG Biotech, High Point, NC) primes in the 
VH germline gene, before the VH CDR3  
5’- TAC TAC GCA GAC TCC GTG AAG –3’ (Tm = 59.8°C) 
reverse primer d:  fdseq1 (MWG Biotech, High Point, NC) primes at the beginning 
of gIII                    
5’- GAA TTT TCT GTA TGA GG – 3’ (Tm = 45.5°C)  
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Reaction mix for one PCR sample (Fermentas, St. Leon-Rot, Germany): 
  10x PCR buffer + (NH4)2SO4 – MgCl2 2.5 µL    
  dNTP mix (10 mM each)   0.5 µL    
  MgCl2 (25 mM)    1.5 µL    
  forward primer (c = 5 pmol·µL-1)  1.25 µL   
  reverse primer (c = 5 pmol·µL-1)  1.25 µL   
  1 U·µL-1 Taq polymerase   0.5 µL    
  sterile H2O     16.5 µL   
  sample DNA     1 µL 
  total volume     25 µL 
2.2.4.3 DNA agarose gel electrophoresis 
Agarose gel electrophoresis is a common effective method to separate DNA by size. The 
phosphate backbone of a DNA molecule is negatively charged so that it will migrate 
towards the positive pole in response to an electric current. The agarose gel is a highly 
cross-linked matrix in which larger DNA molecules will get more entangled than small 
molecules and will therefore migrate slower through the electric field. Not only size but 
also the conformation of the DNA molecule influences the migration speed. When plasmid 
DNA is used e.g., linearised DNA will be more restrained than supercoiled DNA. A 
standard 1% agarose gel can resolve DNA from 0.2 to 30 kb but the resolving range can 
be adapted by varying the concentration of agarose. Ethidium bromide (EtBr) is added to 
the gel for visualisation as it intercalates into the DNA and fluoresces upon UV 
illumination.93 
Procedure: 
A 1.2% agarose gel was prepared by solubilising the agarose in heated 1x TBE buffer. 
Before adding the EtBr, the gel mix was cooled down to hand warmth. The homogenised 
mixture was poured into the gel tray and a comb was inserted carefully. When the gel 
hardened the reservoirs of the chamber were filled until the gel was covered with 1x TBE 
buffer. Before loading the samples and the GeneRuler DNA ladder mix (Fermentas, 
St.Leon-Rot, Germany) a 6x loading dye (Fermentas, St.Leon-Rot, Germany) was added. 
The DNA agarose gel electrophoresis was run at 140 V for one hour. UV visualisation and 
picture capture were performed using the Gel Logic 2200 imaging system (Carestream 
Health Inc., Rochester, NY). 
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Buffers and reagents: 
5x TBE: 
 TRIS pure   445 mM 
 Boric acid  445 mM 
 EDTA-N2  10 mM 
 dissolved in ddH2O 
1.2% agarose gel: 
 1x TBE  200 mL 
 Agarose  2.4 g 
 EtBr   30 µL 
GeneRuler DNA ladder mix (Fermentas, St.Leon-Rot, Germany): 
 
Figure 2.3 GeneRuler DNA ladder mix (Fermentas, St. Leon-Rot, Germany). 
2.2.5 Extraction of the periplasmic scFv 
To obtain a high level production of soluble scFv in E. coli, the protein was expressed in 
HB2151 using the pDN332 expression vector. Due to the pelB leader sequence the scFv 
was directed into the periplasmic space. It was found that the scFv antibodies in the 
periplasm are usually fully folded, correctly processed and contained the intermolecular 
disulfide bonds. An altered version of the protocol by Kipriyanov SM et al. was used for 
the extraction of periplasmic scFv antibodies.94, 95 
Procedure: 
One E. coli HB2151 clone transformed with the scFv-K/F9-pDN332 vector was chosen for 
protein expression. One liter of 2x Ty-Amp-0.1% glucose medium was inoculated with an 
o/n culture of this clone (dilution 1:100). The expression was performed under controlled 
conditions in an Innova 44 incubator (New Brunswick Scientific, Edison, NJ) using a 2 L 
Erlenmeyer flask (VWR, West Chester, PA). The bacterial culture was grown at 37°C with 
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gentle shaking until an OD600 of approximately 0.8 was reached. It was then induced with 
1 mM IPTG and the expression was carried out o/n at 30°C. After centrifugation (8,000 
rpm, 30 min, 4°C) the pelleted bacteria were resuspended in 50 mL of pre-cooled 30 mM 
Tris-HCl, 20% w/v sucrose, 1mM EDTA, pH 7. The solution was incubated for 1 h on ice 
with permanent stirring. After a second centrifugation step (5,000 rpm, 30 min, 4°C) the 
supernatant (S1) was collected. Remaining protein was extracted from the pellet by 
resuspending it in 50 mL ice-cold 5 mM MgSO4 and incubating for 1 h on ice with stirring. 
Centrifugation (5,000 rpm, 30 min, 4°C) left the remaining periplasmic proteins in the 
supernatant (S2). The collected supernatants S1 and S2 were pooled and one Complete 
EDTA-free Protease Inhibitor Cocktail tablet per 50 mL extract volume was added. A 
100 µL sample of each extraction step was taken for analysis in SDS-polyacrylamide gel 
electrophoresis. The pool of S1 and S2 was dialysed against a 100 fold excess of 50 mM 
sodium-phosphate buffer, 300 mM NaCl, 10 mM imidazole, pH 7.5 using a 3,500 MWCO 
membrane tube (Spectra/Por6 molecularporous membrane, Spectrum, Rancho Dominguez, 
CA), o/n at 4°C (see section 2.2.2). Purification of the scFv-K/F9 was accomplished by 
nickel affinity chromatography (see section 2.2.3.4). The purified Gad m 1-specific scFv-
K/F9 was checked by Western Blot (see section 2.2.7) and Dot Blot (see section 2.2.8).  
Buffers and reagents: 
2x Ty medium: 
Peptone   1.6% 
Yeast extract   1% 
NaCl    0.5% 
for plates add 15 g·L-1 of Agar 
pH 7.4 adjusted with NaOH and autoclaved 
2.2.6 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a very common method for the 
separation of proteins according to their molecular weights. SDS, a strong anionic 
detergent, in combination with β-mercaptoethanol, a reducing agent, denature quaternary, 
tertiary and secondary structures of proteins. The denatured polypeptides bind 
approximately 1.4 g SDS per gram protein which masks the initial charges of the proteins. 
They therefore become negatively charged in proportion to their molecular weight. The 
polyacrylamide gel allows now a separation by size due to the fact that different sized 
proteins move at different speeds through the porous gel. Polyacrylamide is a polymer of 
acrylamide, polymerisation is initiated by adding a solution of 10% APS and TEMED to 
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the mix. The determination of the proteins size can be done by using protein markers of 
known molecular weight as a reference. The most commonly used buffer system for SDS-
PAGE is the tris-glycine system described by Laemmli.96 
Procedure: 
The glass plates for casting the gel were assembled in the casting frame and put into the 
casting stand according to the manufacturer’s instructions (Bio-Rad Laboratories Inc., 
Hercules, CA). For analytical purposes, 0.75 mm thick glass spacer plates were used. 
Depending on the approximate size range of the proteins to be analysed, the percent 
acrylamide for the resolving gel has to be chosen following the guidelines below: 
15% gels: 10-35 kDa 
12% gels: 15-45 kDa 
10% gels: 40-100 kDa 
8% gels: 100-200 kDa 
After preparing the resolving gel mix and pouring it between the two glass plates, it is 
overlaid with isopropanol. This prevents oxygen from inhibiting polymerisation and it 
helps to obtain a perfectly horizontal surface on top of the separation gel. Once 
polymerised, the isopropanol can be poured off and the stacking gel mix can be added. A 
comb with the desired well number is inserted carefully afterwards. The protein samples 
are prepared by adding 4x sample buffer (SB), denatured by heating for 5 min at 95°C and 
centrifuged at 13,200 rpm for 5 min. When the stacking gel has polymerised, the plates are 
put into the eloctrophoresis chamber and after removing the comb, the protein samples and 
a protein ladder are loaded into the wells. The electrophoretic apparatus is then filled with 
1x electrophoresis buffer and the SDS-PAGE is carried out at 160 V for one hour.  
Buffers and reagents: 
Acrylamide stock solution (Reagent C): 
Acrylamide  29.2% 
Bis-Acrylamide 0.8% 
dissolved in ddH2O and filtered 
Resolving gel buffer (lower buffer): 
 Tris-HCl, pH 8.8 1.5 M 
 SDS   0.4% 
 dissolved in ddH2O 
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Stacking gel buffer (upper buffer): 
 Tris-HCl, pH 6.8 0.5 M 
 SDS   0.4% 
 dissolved in ddH2O 
4x SB: 
Tris-HCl, pH 6.8 0.125 M 
SDS   10% 
Glycerol  20% 
β-Mercaptoethanol 10% 
Bromphenolblue 0.025% 
dissolved in ddH2O 
10x Electrophoresis buffer (Laemmli buffer): 
Tris pure  0.025M 
Glycine  0.192M 
SDS   1% 
dissolved in ddH2O 
 
Resolving gel Stacking gel  
8% 10% 12% 15% 4.5% 
Reagent C 1.35 mL 1.7 mL 2 mL 2.5 mL 300 µL 
Lower buffer 1.25 mL 1.25 mL 1.25 mL 1.25 mL - 
Upper buffer - - - - 500 µL 
ddH2O 2.4 mL 2 mL 1.75 mL 1.25 mL 1.2 mL 
10% APS 25 µL 25 µL 25 µL 25 µL 20 µL 
TEMED 2.5 µL 2.5 µL 2.5 µL 2.5 µL 1 µL 
 
2.2.6.1 Staining and destaining of SDS-polyacrylamide gels 
Coomassie Blue staining is a rapid and easy method to visualise the location of a protein 
in a gel. The detection depends on a non-specific binding of the dye Coomassie Brilliant 
Blue R-250 to aromatic amino acids. Under acidic conditions the dye binds to proteins 
through ionic interactions between dye’s sulfonic groups and protein amino groups as well 
as through Van der Waals forces. The protein-dye complex stabilises the anionic form of 
the dye producing the blue colour which can then be seen in the gel as protein bands. 
Because Coomassie Blue is mainly non-polar, the staining and destaining solutions 
contain methanol. Dye not bound to any protein is removed by destaining so that protein 
bands appear on a clear background. The detection limit is 0.3 to 1 µg per protein band. 
The staining process can be accelerated by increasing the incubation temperature.97, 98 
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Procedure: 
After SDS-PAGE the gel is put into a plastic tray and stained with staining solution for 45 
min at RT with shaking. It is then transferred into the destaining solution and agitated until 
the background is clear and the protein bands are plainly visible.  
Buffers and reagents: 
Staining solution: 
Coomassie Blue R-250 0.125% 
Methanol   50% 
Acetic acid   10% 
dissolved in ddH2O and filtered 
Destaining solution: 
Acetic acid (100%)  15% 
Methanol   50% 
2.2.7 Western Blotting 
After separating the proteins of a sample by SDS-PAGE, Western Blotting allows the 
detection of one specific protein with the use of poly- or monoclonal antibodies. The 
proteins are transferred to a nitrocellulose (NC) membrane e.g. by electroblotting. Since 
the NC membrane would bind any unspecific protein i.e. antibodies as well, free sticky 
places need to be blocked by any generic protein such as BSA or non-fat dry milk proteins. 
Once blocked, the membrane can be incubated with the specific antibody solution which is 
composed of the primary antibody which recognises the target protein and a secondary 
antibody which binds to the first antibody. The secondary antibody is usually linked to an 
enzyme which catalyses a colourimetric reaction when the appropriate substrate is added, 
so that the target protein gets visualised.  
Procedure: 
After SDS-PAGE the gel, the NC membrane (Pall, Life Sciences, Michigan, USA), 
Whatman paper and the sponges were equilibrated in 1x transfer buffer and assembled as 
shown in Figure 2.4. 
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Figure 2.4 Schematic Western Blot assembly. 
 
The assembly was placed into support pads and blotting was performed with a Transphor 
Electrophoresis Unit (Hoefer Scientific Instruments, San Francisco, CA) in 1x transfer 
buffer by applying a 25 mA electric current for 45 min at 4°C. The NC membrane was 
blocked for 30 min at RT in 10 mL TBST, 3% w/v non-fat dry milk. The primary and 
secondary antibody were diluted according to user’s manual in TBST, 1% w/v BSA and 
the solution was incubated with the membrane o/n at 4°C. The antibody solution was 
decanted the day after and the NC membrane was washed three times for 30 min at RT 
with TBST. As all of the secondary antibodies used were linked to alkaline phosphatise 
(AP), the membrane was equilibrated in AP-buffer. The substrate solution for AP was 
prepared by adding 60 µL of 4-Nitro blue tetrazodium chloride (NBT) and 5-Bromo-4-
chloro-3-indolyl-phosphate (BCIP) each to 10 mL of AP-buffer. The substrate solution was 
poured onto the NC membrane and the colourimetric reaction was allowed to proceed in 
the dark. The reaction was stopped by transferring the membrane into ddH2O.  
 
Primary antibodies used: 
? rabbit polyclonal anti-Gad m 1, diluted 1:10,000  
? mouse monoclonal anti-frog parvalbumin, diluted 1:2,000  
(Sigma-Aldrich Co., St.Louis, MO) 
? mouse polyclonal anti-penta-Histidine, diluted 1:1,000  
(5 Prime Inc., Gaithersburg, MD) 
? monoclonal anti-Gad m 1 scFv-K/F9, 1 µg·mL-1 
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Secondary antibodies used: 
? AP-conjugated AffiniPure rabbit anti-mouse IgG + IgM (H+L),  
diluted 1:5,000 
(Jackson Immuno Research Laboratories Inc., West Grove, PA)  
? AP-conjugated swine polyclonal anti-rabbit, diluted 1:1,1000  
(Dako, Glostrup, Denmark) 
Buffers and reagents: 
10x transfer buffer: 
 Tris-HCl  250 mM, pH 8.3 
 Glycine  192 mM 
 dissolved in ddH2O 
 to 1x buffer 20% methanol was added 
10x Tris buffered saline (TBS): 
 Tris-HCl  0.5 M, pH 7.4 
NaCl   1.5 M 
NaN3   0.5% 
 dissolved in ddH2O 
Tris buffered saline with Tween 20 (TBST): 
 1x TBS + 0.5% v/v Tween 20 
AP-buffer: 
 Tris-HCl  100 mM, pH 9.5 
 NaCl   100 mM 
 MgCl2·6 H2O  5 mM 
 dissolved in ddH2O 
4-Nitro blue tetrazodium chloride (NBT): 
 NBT   50 mg·mL-1 
 dissolved in 70% DMF/H2O 
5-Bromo-4-chloro-3-indolyl-phosphate (BCIP): 
 BCIP   25 mg·mL-1 
 dissolved in ddH2O 
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2.2.8 Dot Blotting 
Dot blotting is a simplified version of the Western Blotting technique. It also relies on the 
principle of detecting a specific protein by the use of antibodies but without prior protein 
sample separation in SDS-PAGE which results in a noticeable gain in time. The protein 
sample is simply dotted on the NC membrane and air dried. Apart from this difference the 
protocols of Western and Dot blotting are the same. 
Procedure: 
The protein samples (1-4 µL) were dotted on NC membrane strips and air dried before 
blocking the strips with TBST, 3% non-fat dry milk for 30 min at RT. After one washing 
step with TBST, the membrane was incubated with the appropriate antibody mix in TBST, 
1% BSA (see section 2.2.7) o/n at 4°C with shaking. Three washing steps with TBST for 
10 min each at RT were followed by equilibration in AP-buffer. The substrate was 
prepared by adding 60 µL of BCIP and NBT each to 10 mL of AP- buffer. The AP 
substrate solution was poured onto the membrane strips and the colourimetric reaction was 
allowed to proceed in the dark. The reaction was stopped by transferring the strips into 
ddH2O. 
2.2.9 Protein concentration determination 
2.2.9.1 Bicinchoninic Acid (BCA) Protein assay 
The Thermo Scientific Pierce BCA Protein Assay (Pierce, Perbio, Rockford, IL) is a 
detergent-compatible formulation based on BCA for the colourimetric detection and 
quantitation of total protein. This assay combines the Biuret reaction, the reduction of 
Cu2+ to Cu+ by protein in an alkaline medium, with the highly sensitive and selective 
colourimetric detection of the cuprous cation (Cu+). The purple-coloured reaction product 
of this assay is formed by the chelation of two molecules of BCA with one cuprous ion. This 
water-soluble complex exhibits a strong absorbance at 562 nm that is nearly linear with 
increasing protein concentrations over a broad working range (20-2,000 μg/mL). For 
quantitaion of an unknown protein sample, concentration is determined with reference to a 
standard curve established by a series of dilution of bovine serum albumine (BSA).99, 100 
Procedure: 
A series of dilutions of standard protein BSA (stock solution; c = 2 mg·mL-1) was prepared 
using the same buffer in which the sample is in. The BCA protein assay was carried out in 
a polystyrene microplate (Greiner Bio-One GmbH, Frickenhausen, Germany). The 
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standards and the sample were pipetted (25 µL) in duplicates and 200 µL of working 
reagent per well was added. The plate was incubated for 30 min at 37°C before measuring 
the absorbance at 562 nm on a plate reader (SpectraMax Plus, Molecular Devices, 
Sunnyvale, CA). The standard curve and sample concentration calculations were evaluated 
with the Soft Max Pro 4.8 software (Molecular Devices, Sunnyvale, CA).  
Buffers and reagents: 
Standard Buffer BSA (2 mg·mL-1) Final concentration 
A 70 µL 10 µL 250 µg·mL-1 
B 72 µL 8 µL 200 µg·mL-1 
C 148 µL 12 µL 150 µg·mL-1 
D 152 µL 8 µL 100 µg·mL-1 
E 156 µL 4 µL 50 µg·mL-1 
F 160 µL - 0 µg·mL-1 
 
Working reagent (Pierce, Perbio, Rockford, IL): 
 50:1 v/v of reagent A:reagent B 
2.2.9.2 NanoDrop Spectrophotometry 
The NanoDrop (ND-1000, Thermo Fisher Scientific Inc., Waltham, MA) 
spectrophotometer measures 1 µL samples without the need of cuvettes or other sample 
containment devices. The sample is pipetted between two fiber optic cables and is then 
analysed by a pulsed xenon flash. Absorption of the sample can be measured in a wide 
range of wavelengths which makes this technique suitable for concentration measurements 
of nucleic acids (DNA, RNA), purified proteins, cell density and general UV-Vis 
spectrophotometry.  
Procedure: 
In order to measure the sample of unknown protein concentration, the spectrophotometer 
needs to be blanked with the dilution buffer used. The sample was applied (1 µL) and 
absorption at 280 nm was measured. The provided software calculated the protein 
concentration of the sample. 
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2.2.10 Isolation of antigen specific scFv-phage clones 
2.2.10.1 Sequential antigen panning of the ETH-2 human antibody phage library 
2.2.10.1.1 Titration of helper phages 
During sequential antigen panning (SAP) of the ETH-2 human scFv phage display library 
the isolated phages need helper phages for their own rescue. A stock of M13KO7 helper 
phages was provided by Mag. Maria Kostadinova (Department of Pathophysiology and 
Allergy Research, Medical University of Vienna, Vienna, Austria) but the titre had to be 
determined for correct use of the phage display library. 
Procedure: 
An E. coli TG1 o/n culture was diluted in LB medium (1:100) and grown at 37°C with 
shaking until an OD600 of 0.8 to 0.9 was reached. Serial dilutions of the helper phage stock 
were prepared as shown in the scheme below (Fig. 2.5). 
 
 
Figure 2.5 Pipetting scheme for helper phage titration. 
 
After infecting the TG1 E. coli cultures with different dilutions of helper phage, the 
cultures were incubated for 15 min at 37°C without movement followed by 30 min 
incubation with shaking. An LB-Kan plate was pre-warmed at 37°C and 10 µL of infected 
TG1 cultures (dilutions 10-7 to 10-14) as well as uninfected TG1 as a control were plated 
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and incubated o/n at 37°C. The helper phage titre was calculated as follows: 15 colonies in 
the 10-8 dilution section = 15·108 phages in 10 µL = 1.5·1011 phages per mL. 
Buffers and reagents: 
Kanamycin (Kan): 
Stock solution: 25 mg·mL-1 in ddH2O 
use 1:1000 for media and plate 
2.2.10.1.2 Sequential antigen panning 
The method of sequential antigen panning (SAP) was used to isolate phage clones 
displaying high-affinity antibodies against the major birch pollen allergen Bet v 1 as well 
as antibodies broadly cross-reactive with Bet v 1 homologues. The success of SAP is based 
on a facilitated selection by sequentially changing the antigen during the panning of phage 
display libraries.101 
Procedure: 
Nunc A/S 5 ml MaxiSorpIM Surface-Immunotubes (Nalge Nunc Intenational, Roskilde, 
Denmark ) were coated with 50 μg·mL-1 Bet v 1 in 4 mL 50 mM NaHCO3, pH 9.6 o/n at 
RT by spinning the tubes on a Rock’n’Roller (neoLab, Heidelberg, Germany). The tubes 
were washed three times with 5 mL PBS and blocked for two hours at RT with PBS, 3% 
non-fat dry milk. The once more washed tubes were incubated with 220 µL of ETH-2 
phage display library (ETH, Swiss Federal Institute of Technology, Zurich) (1013 
phages·mL-1) in 4 mL PBS, 3% non-fat dry milk and spinned for 30 min at RT on the 
Rock’n’Roller. After another 1.5 h of incubation without movement the library was 
decanted and the tubes were first washed ten times with PBST and then ten times with 
PBS. Bound phages were eluted by adding 1 mL freshly prepared 100 mM triethylamine 
and pivoting the tubes for 10 min. The eluates were neutralised by adding 0.5 mL of 1 M 
Tris-HCl pH 7.4. The eluted phages were used to infect 10 mL TG1 E. coli cultures OD600 
0.4 for 30 min at 37°C in a water bath. Three dilutions (10-3, 10-4, 10-5) of infected E. coli 
TG1 were plated on 2x-Ty-Amp-Glu plates for titration. The residual cultures were 
centrifuged (4,000 rpm, 5 min, 4°C), the pellet was resuspended in 500 µL 2x Ty and 
scattered on a large 2x-Ty-Amp-Glu plate. After o/n incubation at 30°C the plates for 
titration were evaluated and E. coli colonies on the large plates were resuspended in 5 mL 
2xTy, 15% glycerol for proliferation. Two mL of the bacterial solution were stored at -
20°C for back-up and 50 µL of infected TG1 cell suspension was used to infect 50 mL 
2xTy-Amp-Glu and grown to an OD600 of 0.4. For phage rescue, 10 mL of infected 
bacterial cultures were incubated with 100 µL of helper phage stock M13K07 
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(1013 cfu·mL-1) for 30 min in a 37°C water bath. After centrifugation (3,300 rpm, 10 min, 
4°C) the pellets were resuspended in 100 mL 2x-Ty-Amp-Kan and grown o/n at 30°C with 
shaking. The cultures were pelleted (4,000 rpm, 30 min, 4°C) and phages left in the 
supernatant were precipitated by adding 25 mL of 20% PEG6000, 2.5 M NaCl, gently 
mixing and incubating on ice for 1 h. The precipitated phages were pelleted (4,000 rpm, 45 
min, 4°C) and resuspended in 40 mL ddH2O. A second precipitation step was performed 
by adding 9 mL 20% PEG6000, 2.5 M NaCl and incubating for 20 min on ice. After 
spinning (4,000 rpm, 30 min, 4°C) the phages were resuspended in 2 mL PBS. One part of 
the isolated phages (500 µL) was used for the next panning round (instead of the ETH-2 
phage display library) whereas the rest was stored at -20°C in 15% glycerol. Phages 
specific for Bet v 1 were enriched by performing three rounds of SAP against Bet v 1 in 
total. Phages cross-reacting with Bet v 1 homologues were enriched by changing the 
antigen in the next rounds to Mal d 1 or Api g 1.  
Buffers and reagents: 
10x Phosphate buffered saline (PBS): 
Na2HPO4·12 H2O 100 mM  
NaCl   1.36 M  
KCl    27 mM 
KH2PO4  18 mM 
dissolved in ddH2O 
Phosphate buffered saline with Tween 20 (PBST): 
 1x PBS + 0.5% v/v Tween 20 
2.2.10.2 Selection of individual phage clones by ELISA 
Enzyme-linked immunosorbent assay (ELISA) is an immunologic method which originally 
uses enzyme-linked immunoglobulins to detect proteins immobilised on an inert surface. 
The linked enzyme usually catalyses a colourimetric reaction by which the antibody-
antigen interaction can be visualised simply by adding the enzyme specific substrate. 
Nowadays several derived kinds of ELISA’s are used.102 
The phage clones isolated from the ETH-2 phage display library carry a scFv antibody 
fused to the pIII coat protein of the phage which is tagged by a C-terminal D3SD3-FLAG-
His6 sequence. This presents the option to detect bound phage clones with anti-His 
enzyme-linked antibodies.  
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Procedure: 
After completing the last round of SAP individual TG1 E. coli colonies were picked with 
sterile pipette tips, transferred into 4 mL of 2x-Ty-Amp-Glu medium and grown o/n at 
37°C with shaking. Fresh 20 mL of 2x Ty-Amp-Glu were inoculated with 200 µL of o/n 
culture and grown at 37°C until an OD600 of 0.4 was reached. Five millilitres of bacterial 
culture were infected with 20 µL of helper phage stock M13K07 (1013 cfu·mL-1) for 30 
min in a 37°C warm water bath. After centrifugation (3,300 rpm, 10 min, 4°C) the pellets 
were resuspended in 10 mL 2x Ty-Amp-Kan and incubated o/n at 30°C with agitation. The 
infected E. coli TG1 cultures were pelleted (4,000 rpm, 25 min, 4°C) leaving the phages in 
the supernatant. Precipitation of the phages was achieved by adding 3 mL 20% PEG6000, 
2.5 M NaCl and incubation on ice for 1 h. After centrifugation (4,000 rpm, 25 min, 4°C) 
the precipitated phages were resuspended in 2 mL PBS.  
Coating of proteins (c = 2 µg·mL-1 in 50 mM NaHCO3, pH 9.6) was carried out in 96 well 
MaxiSorpIM Immuno Plates (Nalge Nunc International, Roskilde, Denmark) by pipetting 
100 µL per well and incubating the covered plate at 37°C for 2 h. After washing the plates 
twice with TBST subsequent blocking was performed by adding 200 µL per well of TBST, 
3% non-fat dry milk and incubating the plates o/n at 4°C. After pouring the blocking 
solution away, two washing steps with TBST followed. The immunoplates were incubated 
with 100 µL per well of a 1:50 dilution of the phage solutions in TBST, 1% BSA o/n at 
4°C. The emptied plates were washed ten times with TBST and the antibody mix of 
primary (mouse polyclonal anti-penta-Histidine, diluted 1:1,000, (5 Prime Inc., 
Gaithersburg, MD)) and secondary (AP-conjugated AffiniPure rabbit anti-mouse IgG + 
IgM (H+L), diluted 1:5,000 (Jackson Immuno Research Laboratories Inc., West Grove, 
PA)) antibody in TBST, 1% BSA was added (100 µL per well). The 3 h incubation period 
at RT was followed by ten washing steps with TBST. The bound phages displaying the 
antigen-specific scFv were visualised by adding 100 µL of AP-substrate solution per well 
and measuring the absorbance at 405 nm after 30 min and 1 h. 
Buffers and reagents: 
AP substrate solution: 
Sigma FAST p-Nitrophenyl phosphate (pNPP) tablets (Sigma-Aldrich Co., 
St.Louis, MO) 
 dissolve 1 tablet set (1x Tris buffer, 1x pNPP) in ddH2O 
 
MATERIALS AND METHODS 
 54 
2.2.11 Plasmid DNA isolation 
Plasmid DNA isolation involves separating the plasmid from the genomic DNA after a 
subtle alkaline cell lysis. This separation step is based on size under denaturing conditions 
during cell lysis. The lysis buffer completely denatures plasmid and genomic DNA but only 
the smaller plasmid DNA can renature during the subsequent neutralisation step. The long 
denatured genomic DNA still bound to proteins can therefore simply be separated by 
centrifugation from plasmid DNA. 
Procedure: 
For the isolation of plasmid pDN332 DNA from phage infected TG1 E. coli cells a 
NucleoSpin® Plasmid preparation kit (Macherey-Nagel, Düren, Germany) was used. The 
manufacturer’s protocol was followed starting with the centrifugation of 3 mL infected E. 
coli TG1 o/n culture (11,000 g, 30 sec, RT). The supernatant was removed completely and 
cells were lysed by adding 250 µL of buffer A1 and vigorous vortexing. After the addition 
of 250 µL of buffer A2 and gently inverting the tubes, the cells were incubated for no 
longer than 5 min at RT. Neutralisation of the reaction mix was done with 300 µL of buffer 
A3 and careful mixing. The lysate was clarified by centrifuging (11,000 g, 5 min, RT) and 
the supernatant was loaded on a NucleoSpin® Plasmid column. Binding of the plasmid 
DNA to the column was achieved by centrifuging (11,000 g, 1 min, RT). The flow-through 
was discarded and the column was washed with 600 µL buffer A4. The column’s silica 
membrane was dried by spinning (11,000 g, 2 min, RT). Bound DNA was eluted with 50 
µL of heated (50°C) ddH2O and collected by centrifugation (11,000 g, 1 min, RT). 
Performance of the plasmid DNA isolation was confirmed by NanoDrop nucleic acid 
spectrophometry at 260 nm (see section 2.2.9.2) and DNA samples were stored at -20°C. 
2.2.12 Expression of allergen specific scFv antibodies 
After several ELISA assays to prove scFv antibody specificity and plasmid DNA isolation 
of selected clones, transformation of a non-suppressor E. coli strain HB2151 followed by 
protein expression and periplasmic extraction of the soluble scFv antibodies were 
performed using the same protocols as in sections 2.2.4.1 and 2.2.5.  
2.2.13 Purification of allergen-specific scFv antibodies 
Several methods were evaluated for the purification of allergen-specific scFv antibodies 
after expression and periplasmic extraction: nickel-based IMAC (see section 2.2.3.4.1), ion 
exchange chromatography (see section 2.2.3.2) or gel filtration chromatography (see 
section 2.2.3.3). The success of these methods was monitored by SDS-PAGE analysis (see 
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section 2.2.6), Western Blotting (see section 2.2.7) and BCA assay (2.2.9.1). But not only 
chromatographic methods were performed; one attempt to purify scFv antibodies included 
also an immunologic method: the immunoprecipitation of FLAG-tagged proteins (see 
section 2.2.3.5). 
2.2.14 Examination of purified scFv antibodies 
2.2.14.1 Evaluation of the specificity and sensitivity of scFv antibodies by ELISA 
The purified scFv antibodies were tested for their antigen specificity and sensitivity by 
varying the following ELISA conditions: scFv antibody concentration, antigen source and 
antigen concentration. The protocol followed for these attempts are described in section 
2.2.10.2. Furthermore the question whether the epitopes recognised by the scFv antibodies 
are of immunologic importance emerged. Thus the ability of the scFv antibodies to inhibit 
specific IgE binding in allergic patients was examined.  
2.2.14.2 Competitive IgE ELISA 
In contrast to prior ELISA assays there are two different primary antibodies in competitive 
ELISA which rival for the binding sites on the surface of the coated protein. The secondary 
enzyme-linked antibody only recognises one of them which gives the investigator the 
possibility to evaluate the binding affinity for the coated protein of the primary antibodies 
used.  
Procedure: 
Coating of proteins (c = 10 µg·mL-1) was carried out as in section 2.2.10.2. After blocking 
and washing the coated plates, the sera of allergic patients and different concentrations of 
scFv antibodies were pre-incubated in a 96 well round bottom micortitre plate for one hour 
at RT. The sera-scFv antibody mixes (100 µL) were transferred into the wells of coated 
and blocked plates. After four hours of incubation at RT, the plates were emptied out and 
100 µL per well of secondary antibody (Alkaline phosphatase conjugated mouse anti-
human IgE monoclonal antibody, BD Biosciences Pharmingen, San Diego, US) (1:1000 in 
TBST, 1% BSA) were added. Subsequent incubation was carried out o/n at 4°C. The wells 
were washed ten times with TBST and 100 µL per well substrate solution was added. The 
absorbance at 405 nm was measured every 30 min. 
2.2.14.3 Mediator release assay from rat basophilic leukaemia cells 
During type I hypersensitivity reactions, allergen-specific IgE antibodies bind to the high-
affinity FcεRI receptor on the surface of mast cells, basophils and eosinophils. Subsequent 
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exposure to the multivalent allergen causes cross-linking of the Fc receptors inducing 
signals which can result in degranulation of the sensitised cells and release of 
inflammatory mediators such as biogenic amines (e.g., histamine), lipid mediators, 
cytokines, enzymes and others.1 This mediator release can be mimicked in vitro by the use 
of rat basophilic leukaemia (RBL) cells that express the α-chain of the human FcεRI 
receptor. The widely used RBL-2H3 transfected cells can bind human IgE and have all 
functional properties of mast cells.103 The mediator release from RBL cells can be 
quantified by the enzymatic activity of β-hexosaminidase which is present in the granules 
and released together with histamine.104 This mediator release assay is widely used for the 
determination of the biological activity of allergen extracts.105 
Here, the sera of birch pollen allergic patients were incubated with cultured RBL cells, so 
that IgE specific for Bet v 1 could bind to the high-affinity FcεRI receptor. By comparing 
the quantified mediator release assays from RBL cells with and without the addition of the 
scFv, the ability of the antibody to inhibit cross-linking of the Fc receptors and therefore 
degranulation can be determined. 
Procedure: 
The RBL-30/25 clone consisting of RBL-2H3 cells transfected with the α-chain of the 
human high-affinity receptor for IgE 105 were cultured in minimal essential medium MEM 
containing 1% 200 mM L-glutamine, 5% foetal calf serum (FCS) and 1 mg·mL-1 geneticin 
G-418. When optimal cell density was reached, the cells were harvested in 10 mL MEM + 
1% L-glutamine + 5% FCS. After centrifugation the cells were washed twice with 10 mL 
MEM and counted. The cell density was adjusted to 2x106 cells/mL with MEM + 1% L-
glutamine + 5% FCS and 50 µL of the cell suspension were seeded into each well of a 
sterile 96-well flat-bottom microtitre plate. The sera of birch pollen allergic patients were 
diluted in MEM and added to the seeded cells (Vserum = 50 µL) as well as MEM medium 
only for the serum negative control, spontaneous release control and total release control. 
A positive control for RBL cells was performed by adding 500 ng of human IgE. The plate 
was incubated o/n at 37°C. The following day, the medium was discarded and the plate 
was washed three times with 75 µL TWB buffer. Then, 100 µL of ACB + D2O, lysis 
buffer, diluted allergen, α-human IgE antibody and allergen-scFv antibody mixes were 
added to the cells like described in table 2.3. 
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Table 2.3 Cross-linking and controls in mediator release assay with RBL cells. 
 
Serum negative control add 100 µL ACB + D2O 
Spontaneous release control add 100 µL ACB + D2O 
Total release control add 100 µL lysis buffer 
Serum positive control add 100 µL of diluted allergen in ACB + D2O 
RBL cells positive control add 100 µL of α-human IgE in ACB + D2O  
(c = 31.6 µg·mL-1) 
scFv inhibition assay add 100 µL of allergen-scFv antibody mix  
in ACB + D2O 
 
After incubation of 1 hour at 37°C, 30 µL of the supernatant were transferred to 50 µL of 
substrate solution in a fresh 96-well microtitre plate. The plate was incubated once more 
for one hour at 37°C. The reaction was stopped by adding 100 µL of stop solution per well. 
The absorbance of the colourimetric reaction was measured at 405-620 nm. The results of 
percent release of RBL cells incubated with sera of birch pollen allergic patients and 
Bet v 1 are given by the formula:  
(ODrelease – ODspontaneous release)/(ODtotal release – ODspontaneous release) x 100 
Buffers and reagents: 
Tyrode’s buffer (20x): 
 NaCl    80 g 
 KCl    2 g 
 NaH2PO4·6H2O  0.65 g 
 MgCl2·6H2O   1 g 
 CaCl2·2H2O   4 g 
 Hepes    24 g 
 dissolve in ddH2O ad 500 mL 
Tyrode’s wash buffer (TWB): 
 Tyrode’s buffer (20x)  25 mL 
 glucose   0.5 g 
 dissolve in 450 mL ddH2O 
 adjust pH to 7.45 with 3M NaOH 
 BSA    0.5 g 
 ddH2O ad 500 mL 
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Allergen challenge buffer (ACB): 
 Tyrode’s buffer (20x)  25 mL 
 glucose   0.5 mL 
 dissolve in 200 mL ddH2O 
 adjust pH to 7.45 with 3M NaOH 
 BSA    0.5 g 
 ddH2O ad 250 mL 
 prepare fresh each time ACB:D2O = 1:1 
Lysis buffer: 
 1% Triton-X100 in PBS 
Substrate solution: 
 Na2HPO4·2H2O    8.9 g 
 p-Nitro-N-acetyl-β-Dglucosaminide  0.65 g 
 dissolve in 400 mL ddH2O 
 adjust pH to 4.5 with 0.4 M citric acid 
 ddH2O ad 500 mL, filtrate 
Stop solution: 
 glycine    15.02 g 
 dissolve in 900 mL ddH2O 
 adjust pH to 10.7 with 3 M NaOH 
 ddH2O ad 1000 mL, filtrate 
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3 Results 
3.1 Chapter 1: Expression and purification of the parvalbumin specific 
single-chain variable fragment antibody scFv-K/F9 and the isotope-
labelled parvalbumin rGad m 1.02 
3.1.1 Expression and purification of the parvalbumin specific scFv-K/F9 
 
 
Figure 3.1 Workflow chart for the expression and purification of scFv-K/F9. 
 
The DNA of the Gad m 1 specific scFv-K/F9 was provided by Mag. Maria Kostadinova 
(Department of Pathophysiology and Allergy Research, Medical University of Vienna, 
Vienna, Austria). The antibody specific for the β-parvalbumin of the Atlantic cod had been 
isolated from the phage display library ETH-2 using sequential antigen panning. The aim 
was to express the soluble antibody in a non-suppressor E. coli strain where it is directed to 
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the periplasmic space due to the pelB leader sequence. For the expression and purification 
of the scFv-K/F9 a stepwise protocol was established (Fig. 3.1). After transformation of 
E. coli HB2151, ten colonies were randomly picked and screened by PCR using the 
oligonucleotide primers DP47CDR2back and fdseq1. The success of transformation was 
validated by agarose gel electrophoresis of the amplified PCR products which migrated at 
approximately 750 bp (Fig. 3.2). 
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Figure 3.2 PCR colony screening products separated by DNA agarose gel electrophoresis 
(colonies 1-10; +, pDN332-scFv-K/F9 as positive control; -, sterile H2O as negative 
control). 
 
The 750 bp band was visible for all ten PCR products as well as for the positive control. 
The negative control did not lead to any amplification. Clone 7 was chosen for scFv-K/F9 
expression. The protein was expressed in 1 L 2x Ty-Amp-0.1% Glucose medium and 
extracted from the periplasm. Each purification step was monitored by 15% SDS-PAGE 
analysis. Molecular weights of marker and proteins are indicated in kDa.  
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Figure 3.3 Coomasssie staining of the scFv-K/F9 expression in E. coli HB2151 and 
periplasmic extraction (P, pellet; S, supernatant). 
 
Figure 3.3 shows Coomassie Brilliant Blue staining of the samples. Two extraction steps 
were performed followed by centrifugation leading to four samples: pellet 1 and 
supernatant 1 and pellet 2 and supernatant 2 after the first and second extraction step, 
respectively. For the purification of the scFv-K/F9 antibody the pool of S1 and S2 were 
dialysed against the binding buffer and applied to a HisTrap crude FF affinity 
chromatography column.  
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Figure 3.4 Nickel-based affinity chromatography fractions separated by 15% SDS-PAGE 
and stained with CBB. 
 
The Gad m 1 specific single chain variable fragment antibody K/F9 was detected as a 
single band in fractions 4 to 7 (Fig. 3.4). Measurement of protein concentration after 
pooling the four fractions, concentrating and dialysing, revealed a total of 1 mg purified 
scFv-K/F9 from one litre of bacterial culture. 
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Figure 3.5 Western blot with scFv-K/F9 against a total protein extract of Atlantic cod and 
birch pollen (BP) separated by 15% SDS-PAGE. 
 
The ability of the antibody to detect Gad m 1 in a protein extract of Atlantic cod was tested 
by Western blotting. Specificity was proved using a birch pollen extract as control sample. 
Figure 3.5 shows that the scFv-K/F9 was able to specifically recognise the 12 kDa protein 
Gad m 1 in the fish extract.  
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3.1.2 Protocol optimisation of the expression and purification of rGad m 1.02 
 
Transformation of E. coli BL21-Codon 
Plus(DE3)-RIPL, Tuner-(DE3)-pLacI and 
Rosetta-gami 2(DE3)pLysS
Expression of rGad m 1.02 in 
E. coli OD2 unlabelled medium
Transformation of E. coli BL21(DE3) 
with pET17b-Gad m 1 expression vector
Expression of rGad m 1.02 in 
M9 minimal medium or
E. coli OD2 unlabelled medium
Cell lysis by French Pressure Cell Press
Dialysis against 
20 mM Bis-Tris-HCl, pH 6.5
Anion exchange chromatography 
(Q Sepharose Fast Flow)
Concentration of proteins 
(Centricon Centripep 3,000 MWCO)
Gel filtration chromatography 
(HiLoad 16/20 Superdex 200 prep grade)
PEG protein precipitation
O
ptim
isation of 
protein expression
a b
O
ptim
isation of 
protein expression
 
Figure 3.6 Workflow chart for the expression and purification of rGad m 1.02. 
 
Expression and purification of unlabelled rGad m 1.02 was performed in different trials to 
yield optimum protein expression. The workflow chart (Fig. 3.6) shows the implemented 
experimental steps. Panel a shows the expression and purification of rGad m 1.02 in E. coli 
BL21(DE3) whereas panel b shows the expression in three other E. coli strains for 
expression optimisation. Chemically competent E. coli BL21(DE3) cells were transformed 
with pET17b-Gad m 1 expression vector. Seven clones were selected for expression in M9 
minimal medium. Two attempts with each clone were carried out, one with IPTG 
induction, the other without. Samples were taken after 3 and 24 hours after induction to 
monitor protein expression levels by 15% SDS-PAGE analysis. Figure 3.7 shows the 
separated samples stained with CBB. The intensity of the protein bands at 12 kDa 
represents the expression levels of rGad m 1 in each clone. After three hours of expression 
no differences in rGad m 1 expression levels could be observed in any of the clones (panel 
a) although other proteins are less expressed when the expression was induced with 1 mM 
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IPTG. Panel b shows protein expression levels after 24 hours. The amount of rGad m 1 
produced is identical for each clone regardless of whether the expression was induced with 
IPTG or not. 
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Figure 3.7 rGad m 1 expression in E. coli BL21(DE3) with (+) or without (-) IPTG 
induction after 3 h (a) and 24 h (b). 
 
Clone 4 was chosen for further experiments. Although expression in M9 minimal medium 
should yield comparable protein amounts as in E. Coli-OD2 CN medium, the expression 
levels in unlabelled medium were examined first. Protein expression was induced with 1 
mM IPTG and samples were taken after 3, 6 and 24 h of induction. The samples were 
analysed in 15% SDS-PAGE and evaluated after CBB staining (Fig. 3.8). 
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Figure 3.8 Comparison of rGad m 1 expression in M9 minimal and E. coli OD 2 
unlabelled medium 3, 6 and 24 h after IPTG induction. 
 
A much higher amount of expressed rGad m 1 was observed at any point of time when E. 
coli OD2 unlabelled medium was used instead of M9 minimal medium (Fig. 3.8). In order 
to further optimise expression conditions other E. coli strains were used as hosts for protein 
expression (Fig. 3.6 b). The E. coli strains BL21-Codon Plus(DE3)-RIPL, Tuner-(DE3)-
pLacI and Rosetta-gami 2(DE3)pLysS were transformed with the expression vector 
pET17b-Gad m 1. Three clones of each strain were chosen for protein expression in E. coli 
OD2 unlabelled medium.  
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Figure 3.9 rGad m 1 expression in three E. coli strains. Induced (+) and not induced (-) 
for 3 h (a) and 24 h (b) with 1 mM IPTG. 
 
Figure 3.9 shows rGad m 1 expression in different E. coli strains and revealed no notable 
improvement compared to expression levels in the previously used E. coli BL21(DE3). 
Thus, E. coli BL21(DE3) was chosen for the expression of isotope-labelled rGad m 1. 
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3.1.3 Expression and purification of isotope-labelled rGad m 1.02 
 
Expression of isotope-labelled rGad m 1.02 
in 1L E. Coli OD2-CN medium
Cell lysis by French Pressure Cell Press
Dialysis against 20 mM Bis-Tris-HCl, pH 6.5
Anion exchange chromatography 
(Q Sepharose Fast Flow)
Concentration of proteins 
(Centricon Centripep 3,000 MWCO)
Gel filtration chromatography 
(HiLoad 16/20 Superdex 200 prep grade)
PEG protein precipitation
 
Figure 3.10 Workflow chart for the expression and purification of isotope-labelled 
rGad m 1.02. 
 
The transformed E. coli BL21(DE3) clone number 4 was chosen for the expression of 13C 
and 15N labelled rGad m 1.02. After optimisation in unlabelled medium, the multi-step 
protocol shown in Fig. 3.10 was established and followed. The expression was carried out 
in 1 L E. Coli OD2-CN medium for 24 h after induction with 1 mM IPTG. Each step of 
cell lysis by French Pressure Cell Press and PEG protein purification was checked by 15% 
SDS-PAGE. The bacterial culture was centrifuged (samples: supernatant and pellet after 
expression) and cell lysis was performed (sample: cell lysis). After another centrifugation 
step (samples: supernatant and pellet after French Press) proteins were precipitated with 
PEG. 
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Figure 3.11 Expression of isotope-labelled rGad m 1, cell lysis by French Pressure Cell 
Press and PEG protein purification (S, supernatant; P, pellet). 
 
The CBB stained gel after separation shows that most of the desired protein remained in 
the supernatant after PEG precipitation (Fig. 3.11). Purification was carried on by dialysis 
of the supernatant against 20 mM Bis-Tris-HCl, pH 6.5 and subsequent Q Sepharose Fast 
Flow anion exchange chromatography. The 1 mL collected fractions 12-30 during gradual 
elution were analysed by 15% SDS-PAGE (Fig. 3.12). 
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Figure 3.12 Anion exchange chromatography fractions 12 to 30 separated by 15% SDS-
PAGE and stained with CBB (S, sample after dialysis; FT, flow-through). 
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Fractions 14 to 27 were pooled and concentrated for the application to a gel filtration 
column using a Centricon Centriprep filter device, MWCO 3,000. Figure 3.13 shows the 
elution profile of the applied sample to a HiLoad 16/20 Superdex 200 prep grade column. 
The arrow indicates where the target protein eluted from the column.  
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Figure 3.13 Purification of isotope-labelled rGad m 1 by gel filtration chromatography. 
 
The target protein was detected as the predominant band of 12 kDa in fractions 15 and 16 
(Figure 3.14). 
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Figure 3.14 Gel filtration chromatography fractions separated by 15% SDS-PAGE and 
stained with CBB (S, applied sample before chromatography). 
 
The two fractions of 5 mL each were pooled and concentrated before detecting rGad m 1 in 
Western blotting with mouse monoclonal antibodies raised against frog parvalbumin 
(Figure 3.15). The target protein is visible as a single band of about 12 kDa.  
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Figure 3.15 Detection of purified 13C and 15N rGad m 1 in Western blotting (lane 1) and 
negative control with secondary antibody only (lane 2). 
 
The purification steps starting with 1 L bacterial culture resulted in 1.5 mg isotope-labelled 
rGad m 1 in total. As the requirement of protein amount needed for NMR spectroscopy 
was not fulfilled, improvement of the yield was necessary. Accordingly, the stored pellet 
after French Pressure Cell Press was thawed and recycled following the workflow chart 
because there was still a lot of the target protein in the pellet after centrifugation of the 
lysed cells (see Figure 3.11). This procedure and another 2 L protein expression and 
purification of 13C and 15N rGad m 1 led to a final outcome of about 4 mg of purified 
protein (results not shown).  
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3.1.4 Investigation of purified scFv-K/F9 and isotope-labelled rGad m 1 
The ability of the scFv-K/F9 antibody raised against nGad m 1 to recognise the isotope-
labelled rGad m 1 was tested by ELISA. Nunc MaxiSorp immunoplates were coated with 2 
µg·mL-1 of nGad m 1, rGad m 1 and Bet v 1 as a negative control. The scFv-K/F9 was 
applied in different concentrations (0.1 – 10 µg·mL-1). 
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Figure 3.16 Ability of scFv-K/F9 to recognise Gad m 1. 
 
The single chain antibody strongly recognised natural Gad m 1 whereas the affinity for 13C 
and 15N rGad m 1 was as weak as for the negative control Bet v 1 (Fig. 3.16). As 
parvalbumin is a calcium binding protein it was thought that calcium concentration could 
play a role for antibody binding. Therefore, the ability of scFv-K/F9 to bind Gad m 1 was 
tested in presence of calcium by adding 0.5 mM CaCl2 and in absence of calcium by 
depleting it with 5 mM ethylene glycol tetraacetic acid (EGTA). Mouse monoclonal anit-
frog parvalbumin antibody was used as a positive conrol.  
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Figure 3.17 Binding capacity of scFv-K/F9 to Gad m 1 in presence or absence of calcium. 
 
The ELISA results in Figure 3.17 show that the scFv-K/F9 strongly recognised the natural 
Gad m 1 independent of the presence of calcium. The monoclonal anti-frog parvalbumin 
antibody, in contrast, only binds to nGad m 1 if calcium is present in the reaction mix. The 
same is true for the monoclonal antibody and the isotope-labelled rGad m 1. Regarding the 
interaction between the scFv-K/F9 and rGad m 1, it was found that the depletion of 
calcium enhances binding although it does not reach the level of scFv-K/F9 and nGad m 1 
interaction.  
In order to resolve the hitherto unknown structure of the β-parvalbumin Gad m 1, the 
whole amount of gained 13C and 15N rGad m 1 (3.5 mg) was provided for NMR 
spectroscopy to Prof. Ana Paula Valente at the Federal University of Rio de Janeiro, 
Brazil. Furthermore, we were interested in locating the epitope of the scFv-K/F9 on the 
surface of Gad m 1. Knowing that the antibody was able to inhibit binding of IgE to 
Gad m 1 in the sera of fish allergic patients, the NMR structure of the scFv-K/F9 bound to 
rGad m 1 would lead to the identification of an important IgE epitope on the surface of 
Gad m 1. This is why in addition to the isotope-labelled protein also 0.4 mg of the scFv-
K/F9 antibody were sent to Prof. Valente. 
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3.2 Chapter 2: Isolation of recombinant scFv antibodies against the 
major birch pollen allergen Bet v 1 and its homologues in plant 
foods 
3.2.1 Sequential antigen panning of the ETH-2 phage display library against Bet v 1 
and its homologues in plant foods 
For the isolation of Bet v 1 specific phages and those cross-reactive with Bet v 1 
homologues, the allergens to be used were checked for their quality. Two micrograms of 
rBet v 1, the 17.5 kDa large major birch pollen allergen (UniProt Acc.No. P15494), 
rApi g 1, the 16.3 kDa large Bet v 1 homologue of celery (UniProt Acc.No. P49372) and 
rMal d 1, the 17.6 kDa large Bet v 1 homologue of apple (UniProt Acc.No. P43211), were 
separated by 15% SDS-PAGE and stained with CBB.  
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Figure 3.18 Allergen check of rBet v 1 and its homologues in celery (rApi g 1) and apple 
(rMal d 1). 
 
Figure 3.18 shows the pure allergens rBet v 1 and rMal d 1 which share 65% amino acid 
sequence identity. The Bet v 1 homologue in celery, rApi g 1 which exhibits 42% amino 
acid sequence homology was considered to be at least 99% pure.  
For the enrichment of Bet v 1 specific phage clones, three panning rounds against Bet v 1 
were performed. In another attempt, it was tried to increase specificity even more through 
depleting unspecific clones by applying them to Api g 1 coated immuno tubes before every 
new panning round. Cross-reactive phage clones were enriched by changing the coated 
antigen after every round (Fig. 3.19). 
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Figure 3.19 Schematic description of the SAP rounds performed. 
 
After each panning round the phage titre was determined. Table 3.1 shows a one hundred 
fold increase between the first and the third panning round, no matter which strategy was 
followed. 
 
Table 3.1 Phage titres during sequential antigen panning against Bet v 1 and its 
homologues. 
 
 panning rounds cfu/mL 
1st round Bet v 1 4x104 
  Bet v 1/Bet v 1 2x104 
2nd round Bet v 1/Api g 1 2x104 
  Bet v 1/Mal d 1 2x105 
  Bet v 1/Bet v 1/Bet v 1 5x106 
3rd round Bet v 1/Api g 1/Mal d 1 3x106 
  Bet v 1/Mal d 1/Api g 1 5x106 
  -   
4th round Bet v 1/Api g 1/Mal d 1/Api g 1 3x106 
  -   
 
To determine how specific the phage clones for the selected antigen were after each round, 
the eluted phages were analysed in ELISA. 
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Figure 3.20 Antigen specificity of phages after each panning round. 
 
When the ETH-2 library was subsequently panned three times against Bet v 1, the isolated 
phages mainly bound to the major birch pollen allergen (Fig. 3.20a). After four rounds of 
SAP with Bet v 1/Api g 1/Mal d 1/Api g 1 the isolated phages predominantly bound to the 
apple homologue Mal d 1 closely followed by Bet v 1. Phages recognising Api g 1 were 
the less abundant (Fig. 3.20b). Changing the order of the used antigens did not affect the 
specificity significantly as seen when antigen panning against Bet v 1/Mal d 1/Api g 1 was 
performed (Fig. 3.20c).  
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Figure 3.21 Polyclonal phage ELISA after three rounds of panning against Bet v 1 and 
depleting Api g 1 phages. 
 
Depleting phages specific for Api g 1 after each panning round against Bet v 1 did not 
significantly change the phage’s recognition pattern when compared to the results where 
Api g 1 specific phages were not removed (Fig. 3.21). 
3.2.2 Selection of individual phage clones and testing for their specificity 
Individual colonies from the titre plates were picked and phages were analysed in 
polyclonal ELISA for their specificity for several antigens. At least ten clones of each SAP 
attempt and panning round were tested for their ability to recognise Bet v 1, Api g 1, 
Mal d 1 and Gad m 1. The parvalbumin Gad m 1 was used as a negative control. The 
phages were evaluated according to their ability to recognise Bet v 1, Mal d 1 or Api g 1 or 
more than one of these allergens, meaning that they were cross-reactive or recognised the 
negative control Gad m 1, meaning that they were unspecific. The pie charts in Figure 3.22 
show the distribution of the tested phage clones in the categories mentioned above. 
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Figure 3.22 Specificity of phage clones after SAP for each selection protocol (a, b, c, d). 
 
Figure 3.22a shows the specificity of 30 phage clones after three rounds of panning against 
Bet v 1. The clones revealed strong binding to Bet v 1, 42% exclusively recognised the 
major birch pollen allergen and none of the other antigens tested. About one quarter (26%) 
of the clones were able to bind to Mal d 1 whereby all of these did also recognise Bet v 1 
and therefore also represented the section of cross-reactive clones (26%). Clones 
categorised as unspecific, meaning that they bound to the negative control allergen 
Gad m 1, and clones which recognised Api g 1 were the less abundant (3%). 
Figure 3.22b shows the specificity of 45 phage clones after three rounds of panning against 
Bet v 1 when Api g 1 specific clones were depleted after each cycle. The overall 
distribution of the phages’ specificity did not change except that one clone was exclusively 
specific for Mal d 1 and therefore not all the clones which recognised Mal d 1 (27%) were 
categorised as cross-reactive (25%). 
After SAP against Bet v 1/Mal d 1/Api g 1 (Fig. 3.22c), 40% of 20 clones did exclusively 
recognise Bet v 1. Only 6% did bind to Api g 1 and 18% to Mal d 1, together building the 
section of cross-reactive clones to Bet v 1 (24%). A four times increase in unspecific 
clones (12%) compared to previous SAP selections (3%) was observed. 
The highest number of unspecific phages was obtained when SAP against 
Bet v 1/Api g 1/Mal d 1/Api g 1 was performed (Fig. 3.22d). Almost one quarter (23%) of 
20 tested clones was non-specific. Specificity for Bet v 1 was the lowest of all four 
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selections (18%) but was the highest for Api g 1 (15%). No clone solely specific for 
Api g 1 or Mal d 1 could be identified. 
After all, clones with a strong signal in ELISA for one or more of the three allergens but no 
signal for Gad m 1 were chosen for further investigation. 
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Figure 3.23 Antigen specificity of selected phage clones. SAP rounds: B/M, 
Bet v 1/Mal d 1; B/A/M/A, Bet v 1/Api g 1/Mal d 1/Api g 1; B/B/B, Bet v 1/Bet v 1/Bet v 1. 
(Bet v 2, a profilin birch pollen allergen; HRP, horseradish peroxidase; Gad m 1, β-
parvalbumin of the Atlantic cod). 
 
Figure 3.23 shows five phage clones each of which represents one pattern group found 
when testing 84 individual phage clones. The phage clone B/M 10 represents the group 
which binds to Bet v 1 and its homologue in apple, Mal d 1. B/A/M/A 1 and B/A/M/A 9 
represent the phages which recognised nearly every protein, even the negative controls 
Bet v 2, HRP and Gad m 1, but giving different signal strengths. B/B/B 2 and B/B/B 08 are 
highly specific for Bet v 1 and do not bind to any other protein at all. No phage clone was 
found which significantly recognised Api g 1 without also binding to the negative controls. 
The phage clones B/M 10, B/B/B 2 and B/B/B 08 were selected for examination and 
further use. For a more detailed characterisation about these phage clones, several other 
Bet v 1 homologues as well as other negative control proteins were chosen. 
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Figure 3.24 Specificity of the phage clones B/M 10, B/B/B 2 and B/B/B 08. 
 
Several different groups of antigens were used for the characterisation of the phage clones: 
lysozyme and DNase, the allergens Gad m 1, Act d 10 and Phl p 5 which are not related to 
Bet v 1, the PR-10 proteins of two bacterial species which like Bet v 1 belong to the 
Bet v 1-like superfamily, the closely Bet v 1-related allergens Gly m 4, Ara h 8, Cora 1.04, 
Mal d 1 and Api g 1 and extracts of celery and birch pollen. The listed antigens were 
chosen because of their homology to the allergens used for SAP rounds from not-related at 
all (enzyme group) to closely related (Bet v 1 homologues in food). 
The control proteins lysozyme and DNase did not give a signal in ELISA with any of the 
clones. The control antigens Gad m 1, kiwi-LTP, Phl p 5 a major allergen from timothy 
grass pollen and the PR-10 homologues of Methanosarcina mazei (M. mazei) and 
Pseudomonas aeruginosa (P. aeruginosa) did not lead to significant signals in any of the 
clones. B/M 10 showed cross-reactivity to Bet v 1 and Mal d 1 but did not bind to any of 
the Bet v 1 homologues in soy (Gly m 4), peanut (Ara h 8), hazelnut (Cor a 1.04) or celery 
(Api g 1). The clones B/B/B 2 and B/B/B 08 display a scFv highly specific for Bet v 1 and 
showed no cross-reactivity at all (Fig. 3.24). 
The single stranded DNA of the three clones was isolated and sent to Eurofins MWG 
Operon for sequencing (Fig. 3.25).  
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Figure 3.25 Agarose gel electrophoresis of isolated ssDNA of the phage clones. 
 
The three phage clones B/M 10, B/B/B 2 and B/B/B 08 were sequenced in both directions 
using the forward primer DP47CDR2back and the reverse primer fdseq1 IRD-800-
fluorescent labelled.  
 
 
Figure 3.26 Amino acid sequence of the phage clones. Variable residues are underlined. 
 
The phage display library ETH-2 was generated by using a constant germline V segment 
DP-47 for the heavy chain to which 4 to 6 completely randomised amino acids were 
appended, so that the beginning of the variable region in the heavy chain of each scFv 
antibody is preceded by the sequence YCAK. The light chain variable domains are either 
composed of the DPL-16 or the DPK-22 germline segment appended to a sequence of six 
random amino acids. The DPL-16 and the DPK-22 germline segments can be identified as 
they terminate with a CNSS or YCQQ amino acid sequence. 
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As the variable regions of scFv antibodies of the ETH-2 phage display library are confined 
to the complementary determining regions three (CDR 3) of the light and heavy variable 
chains, only the amino acid sequence of the concerned domain are depicted in Figure 3.26. 
Sequencing of the three clones revealed sequence identity between clone B/B/B 2 and 
B/B/B 08 whereas the amino acid residues of clone B/M 10 were completely different in 
this region although their variable light chains were all made of the DPL-16 germline 
segment.  
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3.2.3 Expression and purification of recombinant scFv antibodies against chimeric 
proteins of Bet v 1 and Api g 1 for IgE epitope mapping 
 
Selection of Bet v 1 specific phage clones by 
ELISA
Transformation of E. coli HB2151 
Expression of scFv antibodies
Purification of scFv antibodies using:
•affinity chromatography 
(HisTrap crude FF; NiNTA spin columns)
•anti-FLAG immunoprecipitation
•gel filtration chromatography
Extraction of soluble periplasmic
scFv antibodies
Bet v 1 sIgE inhibtion ELISA Histamine release assay from RBL-30/25 cells
 
Figure 3.27 Workflow chart for the expression and purification of Bet v 1 specific scFv 
antibodies. 
 
For the purpose of IgE epitope mapping on Bet v 1, scFv antibodies solely binding to the 
major birch pollen allergen were selected and examined for their interaction with chimeric 
proteins of Bet v 1 and Api g 1 (provided by DI Barbara Gepp, Department of 
Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria). 
The four chimeric proteins Api-Bet-1 to Api-Bet-4 were constructed by grafting the 
surface residues forming the P-loop (Api-Bet-1), the region opposite of the P-loop (Api-
Bet-2), the area surrounding the C-terminus (Api-Bet-3), or the C-terminal alpha helix 
(Api-Bet-4) of Bet v 1 onto Api g 1. 
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Figure 3.28 Binding activity of phage clones to chimeric proteins of Bet v 1 and Api g 1. 
 
The phage clones B/M 09 and B/M 010 were specific for Bet v 1 and did not bind to the 
celery homologue Api g 1, but they showed no binding activity to the chimeric proteins as 
well. The clones B/B/B 08 and B/B/B 2 were highly specific for Bet v 1 and strongly 
recognised the chimeric protein Api-Bet 3. The phage clone B/M 10 also strongly 
recognised Bet v 1 but had much lower binding activity to the chimeras. The clone showed 
weak interaction with Api-Bet 4 and even weaker with Api-Bet 1 (Figure 3.28).  
Clones B/B/B 2, B/B/B 08 and B/M 10 were chosen for expression in E. coli HB2151 and 
soluble scFv antibody expression. After transformation, one clone of each was picked and 
expressed in 2x Ty-Amp-Glu medium. The scFv antibodies were extracted from the 
periplasm and each purification step was monitored by 15% SDS-PAGE analysis. 
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Figure 3.29 CBB staining after 15% SDS-PAGE of the expression and periplasmic 
extraction of scFv antibodies in E. coli HB2151 (P, bacterial pellet; S1, supernatant 1 and 
S2, supernatant 2 after extraction). 
3.2.3.1 Purification through nickel-based affinity chromatography 
For the purification of scFv-B/B/B 2 and scFv-B/B/B 08 the supernatants of the respective 
extractions S1 and S2 were pooled, dialysed against the binding buffer and applied to a 
HisTrap crude FF nickel-based affinity chromatography column. Figure 3.30 shows the 
fractions collections during the scFv-B/B/B 08 purification and then separated by 15% 
SDS-PAGE and stained with CBB. 
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Figure 3.30 Nickel-based affinity chromatography of scFv-B/B/B 08 (Fractions 1-18; FT, 
flow through). 
 
The histidine tagged scFv-B/B/B 08 did not bind to the HisTrap FF crude column as 
expected. The entire proteins are seen as multiple bands in the flow through (Fig. 3.30). 
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The same results were obtained when it was tried to purify scFv-B/B/B 2 antibodies 
(results not shown).  
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Figure 3.31 Concentrated fractions 4 to 7 of scFv-B/B/B 08 nickel-based affinity 
chromatography separated by 15% SDS-PAGE, stained with CBB. 
 
The collected periplasmic extracts S1 and S2 of scFv-B/M 10 were purified by another 
nickel-based affinity chromatographic method using NiNTA spin columns. The 
supernatants were dialysed against binding buffer and applied to the spin columns. 
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Figure 3.32 Nickel-based affinity chromatography using NiNTA spin columns of scFv-B/M 
10 (S, sample; FT, flow through; EL 1, eluate 1 and EL 2 eluate 2). 
 
Figure 3.32 shows the collected fractions separated by 15% SDS-PAGE and stained with 
CBB. The eluates 1 and 2 show enrichment of the scFv-B/M 10 antibody. The two eluates 
Nevertheless, fractions 4 to 7 of scFv-B/B/B 08 of HisTrap FF 
crude chromatography were pooled, concentrated by 
centrifugation with Centricon Centriprep 3,000 MWCO and 
used for Bet v 1 sIgE inhibition ELISA assays (Fig. 3.31). 
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were pooled and stored at -20°C containing 50% glycerol. The same purification method 
was also applied for the scFv-B/B/B 08 antibody.  
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Figure 3.33 15% SDS-PAGE (panel a) and anti-penta His Western blot (panel b) analysis 
of scFv-B/B/B 08 purification using NiNTA spin columns (S, sample; FT, flow through; EL 
1, eluate 1 and EL 2, eluate 2). 
 
Coomassie staining of the fractions separated by 15% SDS-PAGE revealed a light protein 
band in the eluates 1 and 2 but could not be identified as scFv-B/B/B 08 in anti-penta His 
Western blot analysis (Fig. 3.33). Because purification of the scFv-B/B/B 08 and B/B/B 2 
with both nickel-based affinity chromatographic methods failed, immunoprecipitation of 
the FLAG-tagged antibodies was attempted.  
 
3.2.3.2 Purification through FLAG immunoprecipitation 
The supernatants S1 and S2 after periplasmic extraction of both scFv antibodies were 
pooled, dialysed and concentrated. FLAG-immunoprecipitation was performed following 
the user’s manual. 
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Figure 3.34 FLAG IP of scFv-B/B/B 2 and scFv-B/B/B 08 (S, supernatant; W, wash; EL 1, 
eluate 1 and EL 2, eluate 2). 
 
The left panel in Fig. 3.34 shows the success of FLAG immunoprecipitation of scFv-B/B/B 
2. The antibody is seen as the predominant band in eluate 1 and as single band in eluate 2. 
The low molecular weight band <10 kDa could be identified as the FLAG peptide used for 
elution. The right panel shows FLAG-IP of the scFv-B/B/B 08. The antibody was found in 
eluate 1 as a light single band. The procedure was repeated three times in order to increase 
the protein yield. The eluates were pooled, concentrated and analysed in 15% SDS-PAGE. 
Only very low amounts of scFv antibodies could be detected, thus another purification 
method was performed. 
3.2.3.3 Purification through anion exchange and gel filtration chromatography 
The scFv-B/B/B 08 and scFv-B/B/B 2 antibodies were also expressed in E. coli HB2151 
and extracted from the periplasm. The supernatants S1 and S2 were dialysed against the 
binding buffer and applied to a HiTrap Capto Q column. 
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Figure 3.35 scFv-B/B/B 2 purification by anion exchange chromatography. Fractions 2 to 
50 separated by 15% SDS-PAGE and stained with CBB (FT, flow through). 
 
The fractions 2 to 50 of scFv-B/B/B 2 purification by anion exchange chromatography are 
shown in Figure 3.35. The antibody is seen as a prominent protein band in fractions 22 to 
34. Similar results were obtained with scFv-B/B/B 08. Prevalence of the scFv antibody in 
the named fractions was demonstrated in anti-penta His Western blotting (Fig. 3.36). 
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Figure 3.36 Anti-penta His Western blot of fractions 22 to 34 of scFv-B/B/B 2 purification 
by anion exchange chromatography. 
 
The fractions 22 to 34 of scFv-B/B/B 2 anion exchange chromatography were pooled, 
concentrated and applied to a gel filtration HiLoad 16/20 Superdex 200 prep grade column 
to increase the degree of purity. 
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Figure 3.37 Gel filtration chromatography of scFv-B/B/B 2. Fractions separated by 15% 
SDS-PAGE and stained with CBB. 
 
The scFv-B/B/B 2 antibody was found as predominant protein band in fractions 20 and 21 
after gel filtration chromatography. Purity of the antibody in the named fractions was 
considered to be at least 95% pure (Fig. 3.37). Fraction 20 was concentrated and protein 
concentration was measured by BCA protein assay. After expression in 1L medium and 
several purification steps, 0.5 mg of highly pure scFv-B/B/B 2 was obtained. 
 
3.2.3.4 Ability of recombinant scFv antibodies to inhibit sIgE binding to Bet v 1 in 
birch pollen allergic patients 
3.2.3.4.1 Competitive IgE ELISA assays 
The antibodies scFv-B/M 10, scFv-B/B/B 2 and scFv-B/B/B 08 were selected previously 
because of their strong recognition of Bet v 1 without binding to the celery homologue 
Api g 1. Their ability to inhibit sIgE binding to Bet v 1 in birch pollen allergic patients was 
tested by ELISA. All patients’ sera were provided by Dr. Wolfgang Hemmer 
(Floridsdorfer Allergiezentrum, Vienna, Austria). 
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Figure 3.38 Ability of scFv-B/M 10 to inhibit sIgE binding to Bet v 1 in three birch pollen 
allergic patients. 
 
The eluate after nickel-based affinity chromatography of scFv-B/M 10 (Fig. 3.32) was used 
in two different dilutions in ELISA. The antibody was not able to inhibit sIgE binding in 
any of the sera of three birch pollen allergic patients to Bet v 1 at all (Fig. 3.38). 
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Figure 3.39 Ability of scFv-B/B/B 08 to inhibit sIgE binding to Bet v 1 in three birch pollen 
allergic patients. 
 
The pool of concentrated fractions after nickel-based affinity chromatography of scFv-
B/B/B 08 (Fig. 3.31) was used in different dilutions to test the antibody’s sIgE inhibiting 
capability in sera of three birch pollen allergic patients. The scFv-B/B/B 08 was able to 
inhibit binding of IgE from three birch pollen allergic patients’ sera to Bet v 1 up to 25% in 
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patient’s 3 serum, 20% in patient’s 41 serum and 13% in patient’s 5 serum. This means 
that 25%, 20% or 13% less IgE of the patients 3, 41 or 5 respectively is binding to Bet v 1 
when the scFv-B/B/B 08 antibody is present. 
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Figure 3.40 Ability of scFv-B/B/B 2 to inhibit sIgE binding to Bet v 1 in three birch pollen 
allergic patients. 
 
At a concentration of 1 µg·mL-1 the single chain variable fragment B/B/B 2 was not able to 
inhibit IgE binding to Bet v 1 in any of the three birch pollen allergic patients’ sera. In the 
presence of 10 µg·mL-1 of scFv-B/B/B 2 in the sera 17%, 11% and 20% of IgE binding to 
Bet v 1 was inhibited in the patients 9, 16 and 34, respectively. When 50 µg·mL-1 of the 
antibody was added the inhibition of IgE binding to Bet v 1 increased to 50%, 42% and 
33%, respectively. Raising the antibody’s concentration to 100 µg·mL-1 in the patients’ 
sera did not lead to any further augmentation of its inhibition capacity. Although the 
degree of inhibition was patient specific, the maximum of inhibition was reached with 50 
µg·mL-1 scFv antibody concentration (Fig. 3.40). 
In order to confirm these results, additional ELISA inhibition assays were performed with 
the sera of 12 birch pollen allergic patients using 50 µg·mL-1 of scFv-B/B/B 2.  
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Figure 3.41 Ability of scFv-B/B/B 2 to inhibit sIgE binding to Bet v 1 in 12 birch pollen 
allergic patients. 
 
Figure 3.41 shows that scFv-B/B/B 2 was able to inhibit sIgE binding to Bet v 1 up to 45% 
in 12 birch pollen allergic patients. The average percent of inhibition was about 31%. The 
inhibition of IgE binding to Bet v 1 was about 20% in the sera of patients number 21, 24 
and 41, about 30% in the sera of patients number 3, 4, 18, 26 and 28 and approximately 
40% in the sera of patients number 2, 5, 27 and 36. In order to exclude a non-specific 
reaction and to prove that Bet v 1 specific IgE inhibition is a characteristic of scFv-B/B/B 
2, the nGad m 1 specific scFv-K/F9 was also tested for its capability to inhibit sIgE 
binding. 
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Figure 3.42 Ability of scFv-K/F9 to inhibit sIgE binding to Bet v 1 in three birch pollen 
allergic patients. 
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Incubation of scFv-K/F9 with the sera of three birch pollen allergic patients did not result 
in any inhibition of IgE binding to Bet v 1, not even in high concentrations (Fig. 3.42). 
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Figure 3.43 Sensitivity analysis of scFv-B/B/B 2 by ELISA. 
 
The sensitivity of scFv-B/B/B 2 was tested in direct ELISA by coating with 2 µg·mL-1 
Bet v 1 and detecting it with different concentrations (0.01 – 100 µg·mL-1) of scFv-
B/B/B 2. The concentration limit of scFv-B/B/B 2 showing a signal for Bet v 1 in ELISA 
was found to be 10 µg·mL-1 (Fig. 3.43). 
3.2.3.4.2 Mediator release inhibition assays using transfected RBL cells 
The mediator release assays were performed with the scFv-B/B/B 2 which was previously 
shown to be able to inhibit sIgE binding to Bet v 1 of birch pollen allergic patients in 
competitive ELISA. The patients’ sera used were the same as before provided by Dr. 
Wolfgang Hemmer (Floridsdorfer Allergiezentrum, Vienna, Austria). 
After harvesting the cultured RBL cells and sensitising them with IgE from sera of birch 
pollen allergic patients o/n, they were challenged with 10 ng·mL-1 Bet v 1. The scFv-
B/B/B 2 antibody was also added in different concentrations in order to see whether it was 
able to inhibit binding of Bet v 1 to the sensitised RBL cells and therefore prevent the 
high-affinity receptor FcεRI of cross-linking and subsequent degranulation of the cells. 
The parvalbumin specific scFv-K/F9 was used as a negative control in the inhibition 
assays.  
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Figure 3.44 Mediator release inhibition assays with scFv-B/B/B 2 using RBL cells 
sensitised with sera of three birch pollen allergic patients (graph a, OD values; graph b, 
percent inhibition). 
 
Figure 3.44 shows the β-hexosaminidase activity levels in the supernatants of the sensitised 
RBL cells which is an indicator for degranulation and mediator release from the cells. 
When no scFv antibody was added, the cells released 31%, 22% and 15% of  
β-hexosaminidase when challenged with 10 ng·mL-1 Bet v 1 compared to total release of 
lysed cells when sensitised with sera of birch pollen allergic patient 5, 27 and 28 
respectively (results not shown). 
  a 
 b 
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When 0.1 µg·mL-1 of scFv-B/B/B 2 was added, a decrease in the enzymatic activity was 
observed for the cells sensitised with serum 5 and serum 27, revealing 24% and 18% 
inhibition by the scFv antibody, respectively. The same was observed when serum 5 
sensitised cells were challenged with 10 ng·mL-1 Bet v 1 and 1 µg·mL-1 scFv-B/B/B 2 was 
added, resulting in 22% inhibition. The use of higher amounts of scFv-B/B/B 2 did not 
influence binding of Bet v 1 to receptor-bound IgE in any of the sensitised cells. No 
significant changes in β-hexosaminidase activity were observed when RBL cells were 
sensitised with serum of the birch pollen allergic patient 28 no matter which concentration 
of scFv-B/B/B 2 was added. 
In order to see whether the decrease in β-hexosaminidase activity could be attributed to 
specific inhibiting capacities of the scFv-B/B/B 2 antibody, control assays with the 
parvalbumin specific antibody scFv-K/F9 were performed. The RBL cells were sensitised 
as before with sera of birch pollen allergic patients 27 and 28 but not with serum 5 because 
of serum volume limitation. 
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Figure 3.45a OD values of mediator release inhibition assays with scFv-K/F9 using RBL 
cells sensitised with sera of two birch pollen allergic patients. 
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Figure 3.45b Percent inhibition of mediator release inhibition assays with scFv-K/F9 
using RBL cells sensitised with sera of two birch pollen allergic patients. 
 
The levels of β-hexosaminidase activity with sera 27 and 28 sensitised cells and scFv-K/F9 
added in different concentrations shown in Fig. 3.45a were similar to those when scFv-
B/B/B 2 was added. Calculations revealed 17% inhibition by 0.1 µg·mL-1scFv-K/F9 in 
RBL cells sensitised with serum 27 (Fig. 3.45b). Therefore, the observed decrease in 
mediator release when 0.1 µg·mL-1scFv-B/B/B 2 (18% inhibition) were added could not be 
due to inhibition of Bet v 1 binding to IgE on the RBL cells’ surface by the antibody. 
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4 Discussion and Conclusion 
Antibody phage display provides a relatively easy method for the selection of monoclonal 
antibodies with strong affinity for an antigen and high stability.106 Antibody fragments in 
the scFv format are more practical than larger fragments because of their smaller size and 
higher stability but Fab fragments contain more of the native antibody sequence and may 
therefore be better representatives for the natural immunoglobulin.71 The availability of 
entirely human antibodies and the use of parts of the antibody in fusion proteins are major 
reasons why this method is becoming indispensable.107 The antigen binding site of 
recombinant monoclonal antibodies in the scFv format is accessible to engineering in a 
multitude of ways to adapt the use of the antibodies as therapeutics and diagnostics.108 
Most of the structural studies on antigen binding hitherto have been carried out using 
monoclonal Fab fragments as they are easier to crystallise than whole antibodies.109, 110 
This is also true for antibodies in the scFv format. Crystallisation of monoclonal Fabs in 
complex with their cognate antigens have led to the identification of a B-cell epitope of the 
major bee venom allergen and of β-lactoglobulin by X-ray crystallography.111, 112  
The co-crystallisation of a monoclonal scFv antibody with its antigen Methamphetamine 
and the structural information of its epitope have been published recently.109 NMR 
spectroscopy is another tool for mapping precise interaction sites on both an antibody and 
its target protein but is limited by the size of the protein. Thus, small-sized scFv antibodies 
are well suited for NMR spectroscopy of antigen-antibody complexes which has already 
been successfully reported for a scFv-IL-1β complex.113 
Mapping linear epitopes of monoclonal antibodies using recombinant overlapping peptides 
has a long successful history and is still widely used.114 In addition, information about 
conformational IgE epitopes is crucial for accurate diagnosis and treatment of allergy, as 
well as for the study of allergen-antibody interactions.115 For example, conformational 
epitopes of a major latex allergen Hev b 6.02 have been identified with the use of IgE-
blocking monoclonal antibodies and modified variants of the allergen.115 This is 
comparable to our approach where we modified an allergen in a defined way, Api g 1, and 
could deduce the epitopes of scFv antibodies. Given the advantages and possibilities which 
are offered by scFv phage display, it is of high interest to investigate epitopes of scFv 
antibodies able to interact with IgE binding sites of allergens. 
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4.1 Chapter 1: Expression and purification of the parvalbumin specific 
single-chain variable fragment antibody scFv-K/F9 and the isotope-
labelled parvalbumin rGad m 1.02 
IgE-mediated hypersensitivity reactions to β-parvalbumins, which are small calcium-
binding muscle proteins, are responsible for fish allergy in 95% of reported cases.26 The  
β-parvalbumin from Atlantic cod was identified as a novel allergen in 2002 by the use of a 
monoclonal anti-parvalbumin antibody in Western blotting of Atlantic cod protein 
extracts.37 The structures of only a few proteins from the parvalbumin family have been 
determined by X-ray crystallography including the β-parvalbumins of pike 116 and carp 117 
as well as the α-parvalbumin of leopard shark.118 Investigation of potential IgE epitopes on 
the surface of β-parvalbumins is of general interest and was previously performed by 
mutational analysis on the major carp allergen Cyp c 1. This study determined the two 
active calcium-binding domains as highly relevant for IgE binding.40 
The aim of our study was first to express the parvalbumin specific scFv-K/F9 antibody and 
second to express isotope-labelled rGad m 1, the β-parvalbumin of Atlantic cod, for 
structure determination by NMR and mapping of the epitope of scFv-K/F9 on the surface 
of rGad m 1. This is of particular interest as the scFv-K/F9 was able to inhibit sIgE binding 
to parvalbumin in fish allergic patients’ sera by 80%.81 
 
The scFv antibody K/F9 specific for the β-parvalbumin Gad m 1 from Atlantic cod had 
been previously isolated from the ETH-2 phage display library using sequential antigen 
panning.81 Our aim was to express the soluble antibody in a non-suppressor E. coli strain. 
For the expression and purification of the scFv-K/F9 a stepwise protocol had to be 
established. The recombinant antibody was easy to purify by nickel-based chromatography 
due to its penta-His tag (Fig. 3.4, p61). From one litre of bacterial culture a total of 1 mg 
scFv-K/F9 could be purified. The antibody’s specificity was then confirmed in Western 
blotting with a total protein extract of Atlantic cod (Fig. 3.5, p62). The scFv-K/F9 isolated 
from the ETH-2 phage display library was highly specific for its antigen and the detection 
limit for 1 µg·mL-1 scFv-K/F9 was 2 µg·mL-1 nGad m 1 (Fig. 3.16, p71). 
Accurate detection of allergens is important for the standardisation of allergen extracts 
used for allergy diagnosis, the identification of major allergens in environmental samples 
and foods as well as for immunotherapy.119 The scFv-K/F9 was able to specifically detect 
its antigen Gad m 1 in a total protein extract of Atlantic cod, thus illustrating the potential 
use of scFv antibodies in allergen detection and quantification. 
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In order to perform NMR spectroscopy and to resolve the allergen’s structure, isotope-
labelled rGad m 1 needed to be expressed and purified.  
Before the expression of 13C and 15N rGad m 1.02, the protocol was established and 
optimised for the unlabelled protein. The fact that there were no observable differences 
between the expression levels in the three E. coli strains Tuner-(DE3)-pLacI, BL21-Codon 
Plus(DE3)-RIPL and Rosetta-gami 2(DE3)pLysS carrying extra copies of rare tRNA 
genes, revealed that there was no codon bias to overcome (Fig. 3.9, p66). Thus, the initially 
used E. coli strain BL21(DE3) was chosen for the expression of 13C and 15N labelled 
rGad m 1.02. The purification of the isotope-labelled β-parvalbumin was a multi-step 
process which started with a simple mechanical cell lysis followed by protein precipitation 
by PEG (Fig. 3.11, p68) and two chromatographic purification steps (Fig. 3.12, p68 and 
Fig. 3.14, p70). The low outcome of purified protein after expression in 1L medium and 
purification required an improvement in order to avoid high costs for expressing the 
isotope-labelled protein. Therefore, the stored bacterial pellets after French Pressure Cell 
Press were reused for protein extraction and additional expression in 2 L bacterial culture 
was performed. In the end 4 mg of 13C and 15N labelled rGad m 1.02 could be obtained. 
The purity of the protein was checked in 15% SDS-PAGE with Coomassie stain and by a 
monoclonal anti-frog parvalbumin antibody in Western blotting (Fig. 3.15, p70). This 
antibody is known to cross-react with parvalbumins from different fish species.120 
The purified scFv-K/F9 was able to recognise natural Gad m 1 but had much lower affinity 
for the recombinant 13C and 15N labelled Gad m 1 in direct ELISA (Fig. 3.16, p71). As 
Gad m 1 is like all β-parvalbumins a calcium-binding protein and the presence of calcium 
ions was demonstrated to influence protein stability,28 the binding assay was repeated 
under altered conditions. The ability of the single chain antibody K/F9 to bind to natural 
Gad m 1 was unchanged regardless of whether calcium ions were present in the reaction 
mix or not. For the recombinant isotope-labelled Gad m 1 in contrast, the scFv-K/F9 
showed low binding capacity in the presence of calcium ions and a 75% reduced binding 
capacity compared to nGad m 1 when calcium ions were depleted. The monoclonal anti-
frog parvalbumin antibody was able to recognise both nGad m 1 and rGad m 1 in the same 
manner when calcium ions were present but did not bind either one of them in the absence 
of Ca2+ (Fig. 3.17, p72). The reduced binding capacity of scFv-K/F9 to 13C and 15N 
rGad m 1 could not be explained by these assays but structural differences between natural 
and recombinant Gad m 1 were excluded as a cause.  
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Affinity measurements of the antibody for rGad m 1.02 would give further information for 
its decisive characterisation although scFv antibodies have been reported to bind their 
targets with an affinity similar to that of the parent mAb.121 Molecular analyses of scFv 
antibodies in a different study revealed that mutating the nucleotide sequence at single 
positions in the antigen binding site may increase binding affinity.106 Recently, Karsunke et 
al. published that high affinity binding of scFv antibodies may lie in the CDR3 of the 
variable heavy chain.122 Nevertheless, the ability of scFv-K/F9 to recognise isotope-
labelled rGad m 1 was evaluated as sufficiently strong for epitope mapping by NMR. 
4.2 Chapter 2: Isolation of recombinant scFv antibodies against the 
major birch pollen allergen Bet v 1 and its homologues in plant 
foods 
The major aim of this study was to isolate scFv antibodies from the ETH-2 library with 
specificity for the major birch pollen allergen Bet v 1 and its homologues in plant foods. 
This was accomplished by performing different rounds of sequential antigen panning. The 
characterisation of the isolated antibodies was done by ELISA. Another aim was to 
determine the ability of the selected antibodies to inhibit sIgE binding to Bet v 1 in sera of 
birch pollen allergic patients. IgE inhibition patterns, in combination with the antibodies’ 
recognition patterns of the chimeric proteins Api-Bet 1 to Api-Bet 4, resulted in locating 
IgE epitopes on the surface of Bet v 1. 
In 1998 single amino acid residues influencing IgE binding to Bet v 1 were identified by 
mutational analyses and sorted by decreasing importance namely I113, S57, D125, S112 
and F30.123 Today, the focus of many studies is the identification of not only single 
residues crucial for IgE binding but whole conformational IgE epitopes on Bet v 1. To 
date, the C-terminal helix and its preceding loop,56 the surface patches aa 29-58 and aa 73-
103,57 the P-loop region 59 as well as the region aa 127-135 56, 60 have been identified or 
presumed as IgE-reactive epitopes on the surface of Bet v 1. 
 
After completion of the sequential antigen panning rounds, a considerable number of 
individual phage clones (n ≈ 120) was investigated for their specificity for Bet v 1, Mal d 1 
and Api g 1 in direct ELISA. The highest specificity for the major birch pollen allergen 
Bet v 1 was obtained when panning the library three times against Bet v 1 (Fig. 3.22a, 
p77). Statistical analyses indicated that the ETH-2 library only contains a very limited 
number of Api g 1-specific phage clones as no clone specific for this celery allergen could 
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be isolated (Fig. 3.22, p77). Nevertheless, phage clones highly specific for Bet v 1 and 
clones cross-reacting with Bet v 1 and Mal d 1 could be easily isolated and amplified. This 
may also be due to a higher sequence identity between Bet v 1 and Mal d 1 (58%) than 
between Bet v 1 and Api g 1 (40%).49 
Selected phage clones were tested for their ability to recognise chimeric proteins of Bet v 1 
and Api g 1. None of the phage clones bound to the celery homologue Api g 1 (Fig. 3.23, 
p78 and Fig. 3.24, p79). Thus, the scFv antibody epitopes could be inferred from their 
binding to the chimers. The Bet v 1-specific phage clones B/B/B 08 and B/B/B 2 solely 
recognised the chimeric protein Api-Bet 3. Thus, the scFv antibody epitope of the two 
clones could be localised to the C-terminal region of Bet v 1 (Fig. 3.28, p84). One of the 
Mal d 1 cross-reacting phages B/M 10 showed weak interaction with Api-Bet 4 which was 
constructed by grafting the C-terminal α-helix from Bet v 1 onto the surface of Api g 1 
(Fig. 3.28, p84). This led to the conclusion that the epitope of the displayed scFv antibody 
must be located in this region or at least overlap with this area. 
After transformation of the E. coli non-suppressor strain HB2151 and expression, the three 
scFv antibodies were extracted from the periplasm and purified (Fig. 3.29, p85). The scFv-
B/M 10 was purified by nickel-based affinity chromatography and checked by 15% SDS-
PAGE (Fig. 3.32, p86). The antibodies scFv-B/B/B 08 and scFv-B/B/B 2 were detected in 
the collected fractions after anion exchange chromatography and gel filtration 
chromatography by 15% SDS-PAGE (Fig. 3.35, p89 and Fig. 3.37, p90) and anti-penta His 
Western blot (Fig. 3.36, p89). The two purification steps yielded approximately 0.5 mg of 
purified scFv-B/B/B 08 and scFv-B/B/B 2 starting with 1L bacterial culture. Furthermore, 
sequencing of the three clones revealed 100% sequence identity between clone B/B/B 2 
and B/B/B 08 whereas the amino acid residues of clone B/M 10 were completely different 
in the complementary determining region 3 of the scFv antibody (Fig. 3.26, p80). 
Competition ELISA between the scFv antibodies and sIgE of birch pollen allergic patients 
for the binding to Bet v 1 showed that the Bet v 1 specific scFv antibodies were able to 
inhibit sIgE binding to Bet v 1 in a patient specific manner. The potency of inhibiting sIgE 
binding to Bet v 1 in birch pollen allergic patients’ sera varied between 12% and 50% for 
the scFv-B/B/B 2 antibody (Fig. 3.40, p92 and Fig. 3.41, p93). The scFv-B/M 10 antibody, 
in contrast, was not able to inhibit sIgE binding to Bet v 1 in any of the tested patients (Fig. 
3.38, p91). When combining these sIgE inhibition results with those from direct ELISA 
with the chimeric proteins of Bet v 1 and Api g 1, the epitope of scFv-B/B/B 2 and scFv-
B/B/B 08, the C-terminal region of Bet v 1, could be identified as an IgE epitope of 
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Bet v 1. Furthermore, it was presumed that the binding patterns of the patient’s IgE to 
Bet v 1 were individual and further investigations would be worthwhile.  
In mediator release inhibition assays, the scFv-B/B/B 2 did not come up to the expectations 
that it was able to inhibit binding of Bet v 1 to receptor-bound sIgE (Fig. 3.44, p95). As the 
scFv antibody only inhibits sIgE binding to a single epitope, all other IgE epitopes 56, 57, 59, 
60 on the surface of Bet v 1 remain accessible for sIgE binding. Therefore, cross-linking of 
membrane-bound sIgE on the surface of RBL cells could still occur and led to RBL cell 
degranulation. Furthermore, it has been reported that the responsiveness of RBL-2H3 to 
stimulation is highly dependent on experimental conditions including growth phase of the 
cells, growth medium and expression of the human FcεRI α-chain 105, 124 so data from 
degranulation assays should be regarded with care. Although RBL-2H3 cells are widely 
used for mast cell IgE-mediated degranulation much of the data is contradictory and it is 
also speculated that RBL-2H3 share similarities with basophils rather than with other 
histamine-releasing cell types.105 
In summary, our work could locate the epitope of the identical antibodies scFv-B/B/B 08 
and scFv-B/B/B 2 to the C-terminal region of Bet v 1. Furthermore, these scFvs were able 
to inhibit sIgE binding to Bet v 1 in several birch pollen allergic patients to varying 
extents, indicating at least a partial overlap of their epitope with an IgE epitope on Bet v 1. 
The epitope of scFv-B/M 10 could not be located unambiguously but was presumed to be 
situated near the C-terminal helix of Bet v 1. We could clearly show that this scFv 
antibody could not inhibit binding of sIgE to Bet v 1 in birch pollen allergic patients so that 
this epitope could be ruled out as potential IgE-reactive region of Bet v 1. 
We hereby conclude that the combination of epitope grafting and sequential antigen 
panning of scFv antibody phage display libraries is a useful method for IgE epitope 
mapping. 
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5 Summary 
The allergen Gad m 1 from Atlantic cod belongs to the family of β-parvalbumins which are 
responsible for 95% of reported cases of fish allergy. The structural and immunological 
characterisation of allergens is essential for the investigation of cross-reactivity between 
fish species. We therefore aimed to express and purify isotope-labelled rGad m 1 for 
structure determination by NMR spectroscopy. Furthermore, we aimed to map the epitope 
of the previously isolated scFv-K/F9 antibody specific for Gad m 1 and able to inhibit sIgE 
binding to Gad m 1 in sera of fish allergic patients up to 80%.  
The scFv-K/F9 antibody was expressed in E. coli HB2151 and extracted from the 
periplasm. The antibody was purified by nickel-based affinity chromatography due to its 
His6 tag. A total of 1 mg purified scFv-K/F9 was obtained from one litre of bacterial 
culture. The antibody’s ability to recognise Gad m 1 in a total protein extract of Atlantic 
cod was verified by Western blotting. The allergen rGad m 1 was expressed in E. coli 
BL21(DE3) by growing the bacterial culture in 13C and 15N labelled medium. After cell 
lysis by French Pressure Cell Press and PEG protein precipitation the allergen was purified 
by consecutive anion exchange and gel filtration chromatography. The protein was 
identified as a single 12 kDa band by 15% SDS-PAGE and anti-frog parvalbumin Western 
blot. Expression in 3 L bacterial culture resulted in 4 mg pure isotope-labelled rGad m 1. 
The specificity of scFv-K/F9 for isotope-labelled rGad m 1 was tested in ELISA. The 
binding capacity of the scFv antibody was reduced by 75% in the absence of calcium 
compared to nGad m 1 and next to nought in the presence of Ca2+. A causal explanation for 
this observation could not be found by this assay.  
 
Antibodies in the scFv format are the smallest antibody fragments providing the complete 
antigen binding site and are a useful tool for epitope mapping on the surface of allergens. 
Information about conformational IgE epitopes is crucial for the understanding of cross-
reactivity between the major birch pollen allergen Bet v 1 and its homologues in plant 
foods. For this purpose, the ETH-2 phage display library was used to isolate monoclonal 
scFv antibodies specific for Bet v 1 and its homologues in apple, Mal d 1, and in celery, 
Api g 1. 
After sequential antigen panning, the specificity of isolated phage clones was investigated 
in ELISA. Phage clones binding to Api g 1 were less abundant whereas cross-reactive 
clones between Bet v 1 and Mal d 1 and clones exclusively binding to Bet v 1 were easy to 
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isolate. The highest specificity for Bet v 1 was obtained when panning three times against 
the major birch pollen allergen, where 42% of the isolated clones were able to recognise 
Bet v 1. Clones exclusively binding to Bet v 1 were selected for epitope mapping with the 
use of four chimeric proteins of Bet v 1 and Api g 1. The two clones B/B/B 2 and 
B/B/B 08 strongly recognised Bet v 1 and the Api-Bet-3 chimer, locating their epitope to 
the C-terminal region of Bet v 1. The epitope of the clone B/M 10, which bound to Api-
Bet- 4, was found to be in the C-terminal α-helix of Bet v 1. Sequencing of the clones 
revealed 100% identity between B/B/B 2 and B/B/B 08. After soluble expression of the 
scFv antibodies in E. coli HB2151, periplasmic extraction and a multi-step purification, the 
antibodies were used in sIgE inhibition ELISA. The scFv-B/B/B 2 was able to inhibit sIgE 
binding to Bet v 1 in sera of 12 birch pollen allergic patients by 12% to 50% whereas the 
scFv-B/M 10 was not able to inhibit sIgE binding in any of the patients’ sera. The 
combination of epitope mapping and sIgE inhibition ELISA defined the C-terminal region 
of Bet v 1 as a highly relevant IgE epitope.  
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6 Zusammenfassung 
Die Vertreter der β-Parvalbumin Proteinfamilie, zu denen auch das Allergen Gad m 1 aus 
Kabeljau zählt, sind verantwortlich für 95% der berichteten Fälle von Fischallergie. Die 
strukturelle und immunologische Charakterisierung von Allergen ist grundlegend für ein 
besseres Verständnis der hohen Kreuzreaktivität von Fischarten. Daher wurde im Zuge 
dieser Arbeit isotopenmarkiertes rGad m 1 exprimiert und aufgereinigt für spätere 
Strukturbestimmung mittels NMR-Spektroskopie. Außerdem soll das Epitop des Gad m 1 
spezifischen scFv-K/F9 Antikörper mit NMR-Spektroskopie bestimmt werden, da dieser 
die Bindung von sIgE aus Seren fischallergischer Patienten an Gad m 1 um bis zu 80% 
inhibieren konnte. 
Der scFv-K/F9 Antikörper wurde in E. coli HB2151 exprimiert und aus dem Periplasma 
extrahiert. Der Antikörper konnte dank His6-Tag mittels Nickel-Affinitätschromatographie 
aufgereinigt werden. Aus einem Liter bakterieller Kultur konnte ein Ertrag von 1 mg 
reinem scFv-K/F9 erzielt werden. Die Spezifität des Antikörpers wurde in einem Western 
Blot überprüft, wo er in einem Kabeljau Gesamtproteinextrakt spezifisch an Gad m 1 band. 
Das Allergen rGad m 1 wurde in E. coli BL21(DE3) exprimiert, indem die bakterielle 
Kultur in 13C und 15N markiertem Medium gezüchtet wurde. Nach Zelllyse mittels French 
Pressure Cell Press und PEG Proteinfällung wurde das Allergen durch aufeinanderfolgende 
Anionentauscher- und Gelfiltrations-Chromatographie aufgereinigt. Das Protein wurde als 
12 kDa Bande in 15% SDS-PAGE und anti-Frosch Parvalbumin Western Blot 
nachgewiesen. Aus 3 L bakterieller Kultur konnten 4 mg reines isotopenmarkiertes 
rGad m 1 gewonnen werden. Die Spezifität des scFv-K/F9 Antikörpers für 
isotopenmarkiertes rGad m 1 wurde in ELISA getestet. Die Bindungskapazität des 
Antikörpers für rGad m 1 in der Abwesenheit von Ca2+war um 75% reduziert verglichen 
mit der für nGad m 1 und fast null in der Anwesenheit von Ca2+. Die Ursache für diese 
Beobachtung konnte in dieser Studie nicht ermittelt werden. 
 
Antikörper im scFv Format sind die kleinsten Antikörperfragmente, die über eine 
vollständige Antigenbindungsstelle verfügen und sich daher besonders für 
Epitopbestimmungen an der Oberfläche von Allergenen eignen. Die Kenntnis über 
konformationelle IgE Epitope ist grundlegend für das Verständnis der Kreuzreaktivität von 
Bet v 1, dem Hauptallergen aus Birkenpollen, und seinen Homologen aus pflanzlichen 
Nahrungsmittel. Aus diesem Grund wurde die ETH-2 Phagenbibliothek verwendet, um 
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monoklonale scFv Antikörper spezifisch für Bet v 1 und seine Homologen aus Apfel 
(Mal d 1) und Sellerie (Api g 1) zu isolieren.  
Die Spezifität der isolierten Phagenklone nach unterschiedlichen panning-Runden wurde in 
direkten ELISA Versuchen getestet. Phagenklone, die an Api g 1 banden, waren am 
Seltensten, während kreuzreaktive Klone mit Bet v 1 und Mal d 1 genauso wie Klone, die 
ausschließlich Bet v 1 erkannten, einfach zu isolieren waren. Die Spezifität für Bet v 1 war 
am Höchsten, wenn drei panning-Runden gegen das Hauptallergen aus Birke selbst 
durchgeführt wurden. In diesem Fall waren 42% der getesteten Klone höchst spezifisch für 
Bet v 1. Klone, die ausschließlich Bet v 1 erkannten, wurden für Epitopbestimmungen in 
ELISA Versuchen mit Hilfe von vier chimären Proteinen aus Bet v 1 und Api g 1 
auserwählt. Die Klone B/B/B 2 und B/B/B 08 wiesen hohe Bindungskapazität für Bet v 1 
und Api-Bet-3 auf, sodass ihr Epitop auf die C-terminale Region von Bet v 1 lokalisiert 
werden konnte. Das Epitop des Klons B/M 10 hingegen konnte aufgrund seiner Spezifität 
für Bet v 1 und Api-Bet-4 auf die C-terminale Helix von Bet v 1 lokalisiert werden. Die 
Sequenzierung der Phagen-DNA zeigte, dass die Klone B/B/B 2 und B/B/B 08 zu 100% 
ident waren. Die löslichen scFv Antikörper wurden in E. coli HB2151 exprimiert, aus dem 
Periplasma extrahiert und nach einem mehrstufigen Aufreinigungsprozess für ELISA 
Inhbitionsversuche verwendet. Der scFv-B/B/B 2 Antikörper war in der Lage die Bindung 
von sIgE aus Seren von 12 Birkenpollenallergikern auf Bet v 1 um 12-50% zu inhibieren. 
Der scFv-B/M 10 Antikörper hingegen konnte nicht mit sIgE um die Bindung zu Bet v 1 
konkurrieren. Das Zusammenführen der Ergebnisse aus den Epitopbestimmungen und 
jenen aus den ELISA Inhibitionsversuchen führte zu der Schlussfolgerung, dass es sich bei 
der C-terminalen Region von Bet v 1 um ein bedeutendes IgE Epitop handelt. 
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